[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 44 of about 44
1. Kodera Y, Fujiwara M, Koike M, Nakao A: Chemotherapy as a component of multimodal therapy for gastric carcinoma. World J Gastroenterol; 2006 Apr 7;12(13):2000-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy as a component of multimodal therapy for gastric carcinoma.
  • Prognosis of locally advanced gastric cancer remains poor, and several multimodality strategies involving surgery, chemotherapy, and radiation have been tested in clinical trials.
  • Phase III trial testing the benefit of postoperative adjuvant chemotherapy over treatment with surgery alone have revealed little impact on survival, with the exception of some small trials in Western nations.
  • Results from Japanese trials suggest that moderate chemotherapy with oral fluoropyrimidines may be effective against less-advanced (T2-stage) cancer, although another confirmative trial is needed to prove this point.
  • Investigators have recently turned to neoadjuvant chemotherapy, and some promising results have been reported from phase II trials using active drug combinations.
  • In 2005, a large phase III trial testing pre- and postoperative chemotherapy has proven its survival benefit for resectable gastric cancer.
  • Since the rate of pathologic complete response is considered to affect treatment results of this strategy, neoadjuvant chemoradiation that further increases the incidence of pathologic complete response could be a breakthrough, and phase III studies testing this strategy may be warranted in the near future.
  • [MeSH-major] Stomach Neoplasms / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 2005 Jun 1;90(3):174-86; discussion 186-7 [15895444.001]
  • [Cites] Ann Oncol. 2005 May;16 Suppl 4:iv102-105 [15923408.001]
  • [Cites] Ann Surg. 2002 Apr;235(4):499-506 [11923605.001]
  • [Cites] Ann Surg Oncol. 2002 Apr;9(3):278-86 [11923135.001]
  • [Cites] Tumori. 2002 Jan-Feb;88(1):21-7 [12004845.001]
  • [Cites] Can J Surg. 2002 Dec;45(6):438-46 [12500920.001]
  • [Cites] Int J Cancer. 2003 May 20;105(1):136-43 [12672044.001]
  • [Cites] Anticancer Res. 2003 Jan-Feb;23(1B):583-7 [12680150.001]
  • [Cites] Eur J Surg. 2002;168(11):597-608 [12699095.001]
  • [Cites] Cancer Sci. 2003 Jan;94(1):112-8 [12708484.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2282-7 [12805327.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 2:ii45-7 [12810458.001]
  • [Cites] Int J Oncol. 2003 Nov;23(5):1419-23 [14532985.001]
  • [Cites] Lancet Oncol. 2003 Dec;4(12):760-8 [14662433.001]
  • [Cites] Br J Cancer. 2003 Dec 15;89(12):2207-12 [14676796.001]
  • [Cites] Br J Cancer. 2004 Feb 9;90(3):665-71 [14760382.001]
  • [Cites] Am J Surg. 2004 Mar;187(3):440-5 [15006580.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3618-30 [15289487.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3631-8 [15289488.001]
  • [Cites] World J Surg. 1977 Mar;2(1):213-21 [868069.001]
  • [Cites] Semin Surg Oncol. 1991 Nov-Dec;7(6):365-72 [1759085.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):536-40 [1548518.001]
  • [Cites] J Clin Oncol. 1992 Dec;10(12):1933-42 [1453207.001]
  • [Cites] BMJ. 1993 Sep 4;307(6904):591-6 [8401015.001]
  • [Cites] J Clin Oncol. 1994 May;12(5):970-4 [8164049.001]
  • [Cites] J Am Coll Surg. 1995 Jul;181(1):56-64 [7599772.001]
  • [Cites] Ann Surg Oncol. 1995 Nov;2(6):488-94 [8591078.001]
  • [Cites] Cancer. 1995 Oct 15;76(8):1302-12 [8620402.001]
  • [Cites] Semin Oncol. 1996 Jun;23(3):352-9 [8658219.001]
  • [Cites] Semin Oncol. 1996 Jun;23(3):379-89 [8658222.001]
  • [Cites] Br J Surg. 1996 Nov;83(11):1604-7 [9014687.001]
  • [Cites] Ann Surg Oncol. 1997 Apr-May;4(3):203-8 [9142380.001]
  • [Cites] Cancer. 1997 Dec 15;80(12):2333-41 [9404711.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1490-3 [9552056.001]
  • [Cites] J Clin Oncol. 2005 Jul 10;23(20):4509-17 [16002841.001]
  • [Cites] Int J Oncol. 2005 Sep;27(3):637-44 [16077911.001]
  • [Cites] Br J Cancer. 2000 Aug;83(3):391-6 [10917557.001]
  • [Cites] Ann Oncol. 2000 Jul;11(7):837-43 [10997811.001]
  • [Cites] Cancer. 2001 Mar 1;91(5):918-27 [11251943.001]
  • [Cites] Br J Cancer. 2001 Apr 6;84(7):878-80 [11286464.001]
  • [Cites] Int Surg. 2000 Jul-Sep;85(3):209-15 [11324997.001]
  • [Cites] Cancer. 2001 Jun 1;91(11):2165-74 [11391598.001]
  • [Cites] Ann Surg Oncol. 2001 Jul;8(6):519-24 [11456051.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3810-5 [10577853.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):889-94 [10705010.001]
  • [Cites] Oncology. 2000 Apr;58(3):191-7 [10765119.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):279-86 [11466680.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] Cancer. 2001 Aug 15;92(4):753-60 [11550144.001]
  • [Cites] Ann Oncol. 2001 Aug;12(8):1178-80 [11583204.001]
  • [Cites] Circulation. 2002 Mar 12;105(10):1170-5 [11889009.001]
  • [Cites] Surgery. 1998 May;123(5):573-8 [9591011.001]
  • [Cites] J Am Coll Surg. 1999 Jan;188(1):27-32 [9915239.001]
  • [Cites] Int J Cancer. 1999 Mar 15;80(6):827-41 [10074914.001]
  • [Cites] N Engl J Med. 1999 Mar 25;340(12):908-14 [10089184.001]
  • [Cites] Ann Surg. 1999 Mar;229(3):303-8 [10077040.001]
  • [Cites] Br J Cancer. 1999 Mar;79(9-10):1522-30 [10188901.001]
  • [Cites] Am J Clin Oncol. 1999 Jun;22(3):262-6 [10362333.001]
  • [Cites] Lancet. 1999 Jul 24;354(9175):273-7 [10440302.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):319-23 [10458249.001]
  • [Cites] Am J Surg. 1999 Sep;178(3):256-62 [10527450.001]
  • [Cites] Cancer. 1956 Nov-Dec;9(6):1153-9 [13383445.001]
  • [Cites] Adv Clin Chem. 2004;38:87-110 [15521189.001]
  • [Cites] Cancer Chemother Rep. 1964 Feb;35:1-111 [14117037.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Sep;54 Suppl 1:S25-31 [15309511.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1237-44 [15718321.001]
  • (PMID = 16610047.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 70
  • [Other-IDs] NLM/ PMC4087675
  •  go-up   go-down


2. Fleming GF, Sill MW, Darcy KM, McMeekin DS, Thigpen JT, Adler LM, Berek JS, Chapman JA, DiSilvestro PA, Horowitz IR, Fiorica JV: Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol; 2010 Jan;116(1):15-20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.
  • PURPOSE: This study evaluated efficacy of single-agent trastuzumab against advanced or recurrent HER2-positive endometrial carcinoma (EC), and explored predictors for HER2 amplification.
  • PATIENTS AND METHODS: Eligible patients had measurable stage III, IV, or recurrent EC.
  • There was no limit on prior therapy although total prior doxorubicin dose was limited to 320 mg/m(2).
  • Thirty-four women were enrolled; 1 was excluded (refused treatment); and 18 had tumors with known HER2 amplification.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827857787 for PMID:19840887 [PharmGKB] .
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Clin Pract Oncol. 2006 May;3(5):269-80 [16683005.001]
  • [Cites] Gastric Cancer. 2005;8(4):206-8 [16328593.001]
  • [Cites] Int J Gynecol Cancer. 2006 May-Jun;16(3):1370-3 [16803532.001]
  • [Cites] Int J Gynecol Cancer. 2006 Sep-Oct;16(5):1897-902 [17009989.001]
  • [Cites] Clin Cancer Res. 2007 Oct 1;13(19):5883-8 [17908983.001]
  • [Cites] J Clin Oncol. 2006 May 20;24(15):2376-85 [16710036.001]
  • [Cites] N Engl J Med. 2007 Jul 5;357(1):39-51 [17611206.001]
  • [Cites] Gynecol Oncol. 2008 Jan;108(1):3-9 [17945336.001]
  • [Cites] Cancer Res. 2008 Mar 1;68(5):1471-7 [18316611.001]
  • [Cites] Front Biosci. 2008;13:3906-12 [18508484.001]
  • [Cites] Int J Gynaecol Obstet. 2008 Aug;102(2):128-31 [18555254.001]
  • [Cites] Int J Gynecol Cancer. 2008 Nov-Dec;18(6):1339-43 [18221484.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2639-48 [10561337.001]
  • [Cites] Mod Pathol. 2004 Mar;17(3):227-87 [14752523.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):737-44 [8622019.001]
  • [Cites] Stat Med. 1997 Aug 30;16(16):1791-802 [9280033.001]
  • [Cites] Stat Med. 1998 Oct 30;17(20):2301-12 [9819829.001]
  • [Cites] Gynecol Oncol. 2005 Jul;98(1):24-30 [15894362.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6422-30 [16166416.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10669-73 [16322209.001]
  • [CommentIn] Gynecol Oncol. 2010 Jul;118(1):95-6; author reply 96-7 [20172595.001]
  • (PMID = 19840887.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA027469-28; United States / NCI NIH HHS / CA / U10 CA037517-24; United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / U10 CA027469; United States / NCI NIH HHS / CA / U10 CA037517; United States / NCI NIH HHS / CA / CA 37517; None / None / / U10 CA027469-28; None / None / / U10 CA037517-24
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  • [Other-IDs] NLM/ NIHMS154884; NLM/ PMC2804260
  •  go-up   go-down


3. Javle M, Hsueh CT: Updates in Gastrointestinal Oncology - insights from the 2008 44th annual meeting of the American Society of Clinical Oncology. J Hematol Oncol; 2009 Feb 23;2:9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have reviewed the pivotal presentations rcelated to colorectal cancer (CRC) and other gastrointestinal malignancies from 2008 annual meeting of the American Society of Clinical Oncology (ASCO).
  • The report on KRAS status in patients with metastatic CRC receiving epidermal growth factor receptor (EGFR) targeted antibody treatment has led to a change in National Comprehensive Cancer Network guideline that recommends only patients with wild-type KRAS tumor should receive this treatment.
  • The results of double biologics (bevacizumab and anti-EGFR antibody) plus chemotherapy as first-line treatment in patients with metastatic CRC has shown a worse outcome than bevacizumab-based regimen.
  • Microsatellite Instability has again been confirmed to be an important predictor in patients with stage II colon cancer receiving adjuvant treatment.
  • Adjuvant gemcitabine therapy for pancreatic cancer was investigated by the CONKO-001 study; this resulted in superior survival as compared with observation and can be regarded as an acceptable option, without the addition of radiotherapy.
  • Second-line therapy for advanced pancreatic cancer with 5-fluorouracil and oxaliplatin resulted in a survival benefit.
  • Irinotecan plus cisplatin and paclitaxel plus cisplatin result in similar survival when combined with radiotherapy for esophageal cancer.
  • The novel fluoropyrimidine S1 appears to be active in gastric cancer, as a single agent or as combination therapy.
  • Adjuvant intraperitoneal mitomycin-C may decrease the incidence of peritoneal recurrence of gastric cancer.
  • Sorafenib is an effective agent in Asian patients with hepatocellular carcinoma secondary to hepatitis B; its utility in child's B cirrhosis remains to be proven.
  • Sunitinib is also an active agent in hepatocellular carcinoma, and may represent an alterative to sorafenib for advanced disease.
  • [MeSH-major] Carcinoma / therapy. Congresses as Topic. Gastrointestinal Neoplasms / therapy. Medical Oncology / trends
  • [MeSH-minor] Biliary Tract Neoplasms / therapy. Chemotherapy, Adjuvant / methods. Chemotherapy, Adjuvant / trends. Humans. Liver Neoplasms / therapy. Neoplasm Metastasis. Neoplasm Staging / methods. Pancreatic Neoplasms / therapy. Societies, Medical

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2001 Nov 10;358(9293):1576-85 [11716884.001]
  • [Cites] Ann Surg Oncol. 2012 Jan;19(1):68-74 [21879261.001]
  • [Cites] N Engl J Med. 2003 Jul 17;349(3):247-57 [12867608.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4592-6 [14673047.001]
  • [Cites] Ann Oncol. 2004 Aug;15(8):1210-4 [15277260.001]
  • [Cites] J Biol Chem. 1990 May 15;265(14):7709-12 [2186024.001]
  • [Cites] J Natl Cancer Inst. 1998 May 6;90(9):675-84 [9586664.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1803-10 [15677699.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2310-7 [15800321.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):394-400 [16421419.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4914-21 [17050875.001]
  • [Cites] J Clin Oncol. 2007 Jan 20;25(3):326-31 [17235048.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3205-9 [17664467.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4557-61 [17876013.001]
  • [Cites] Clin Cancer Res. 2007 Nov 15;13(22 Pt 2):6913s-20s [18006800.001]
  • [Cites] Lancet. 2007 Dec 15;370(9604):2020-9 [18083404.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):374-9 [18202412.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Ann Oncol. 2008 Apr;19(4):734-8 [18272912.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1626-34 [18316791.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] J Clin Oncol. 2008 Dec 20;26(36):5918-22 [19029412.001]
  • [Cites] J Clin Oncol. 2009 Jun 1;27(16):2598-603 [19164203.001]
  • [Cites] J Clin Oncol. 2009 Jul 10;27(20):3385-90 [19414665.001]
  • [Cites] J Nucl Med. 2009 Jul;50(7):1036-41 [19525451.001]
  • [Cites] J Clin Oncol. 2010 Jul 20;28(21):3491-7 [20530271.001]
  • [Cites] J Thorac Oncol. 2010 Sep;5(9):1472-6 [20631636.001]
  • [Cites] Ann Surg Oncol. 2003 Jun;10(5):539-45 [12794020.001]
  • (PMID = 19236713.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] eng
  • [Publication-type] Congresses
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2654905
  •  go-up   go-down


Advertisement
4. Ychou M, Senesse P, Quénet F: [Update on gastroenterology]. Bull Cancer; 2000 Jun;87(6):455-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the field of mass detection of colorectal cancer by Hemoccul test, the results of the Burgundy study confirm the two european studies previously published and encourage to extend this training to the whole country.
  • When genetic markers are performed in a population selected according to these type I criteria, HNPCC mutation could be detected in 28% of cases.
  • In colorectal cancer surgery, the debate remains open on the place of coeliosurgery.
  • A US study has confirmed the prognostic value of the number of lymph nodes analyzed after resection of colorectal cancer.
  • In adjuvant treatment of stage II colon cancer, two contradictory publications have been reported in the Journal of Clinical Oncology.
  • However, the results of the Impact B2 Group are more consistent and support the fact that chemotherapy cannot be recommended as a standard treatment in state II colon cancer.
  • Concerning the chemotherapy of metastatic colorectal cancer, important results have been published in second line therapy showing the superiority of Campto compared to best supportive care or 5FU based chemotherapy both in term of overall survival and quality of life.
  • In first line chemotherapy, the superiority of bi-therapies (LV5FU2 and oxaliplatin or LV5FU2 and irinotecan) has been confirmed compared to LV5FU2 alone.
  • A recent publication showed that patients older than 70 years tolerate chemotherapy for colorectal cancer as well as younger patients with the same efficacy.
  • In esophagus carcinoma, the most important study didn't show any efficacy of neoadjuvant chemotherapy by 5FU-cisplatin in operable adenocarcinoma of squamous carcinoma of esophagus.
  • The final results of dutch's study in node dissection for gastric cancer do not find any benefit in overall survival comparing D2 versus D1 dissection with a substantial increase in morbidity and mortality in the D2 arm, specially when splenopancreatectomy was performed.
  • [MeSH-major] Colorectal Neoplasms, Hereditary Nonpolyposis. Esophageal Neoplasms / drug therapy. Stomach Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Biopsy, Needle / methods. Combined Modality Therapy. Genetic Testing. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis. Mass Screening / methods. Occult Blood

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10903787.001).
  • [ISSN] 0007-4551
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] FRANCE
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 22
  •  go-up   go-down


5. Imamura H, Anami S, Watanabe M, Kishimoto T, Miyazaki Y, Kato H, Usui T, Masutani S, Tomotsu K, Furukawa H: [Induction of liaison-clinical pathway for patients with gastric cancer undergoing adjuvant chemotherapy using S-1 after curative gastrectomy]. Gan To Kagaku Ryoho; 2008 Aug;35(8):1361-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Induction of liaison-clinical pathway for patients with gastric cancer undergoing adjuvant chemotherapy using S-1 after curative gastrectomy].
  • The efficacy of adjuvant chemotherapy using S-1 for one year after curative surgical treatment for patients with gastric cancer of stage II or III was reported as the result of randomized controlled trial named ACTS-GC in 2007.
  • Therefore the number of patients undergoing this adjuvant chemotherapy is predicted to be rapidly increasing in near future.
  • On the other hand, the government promotes to construct the liaison-clinical pathway for patients with major carcinoma as a policy in 2007.
  • According to these two backgrounds, liaison-clinical pathway for patients with gastric cancer undergoing adjuvant chemotherapy using S-1 after curative gastrectomy has been induced in our institute from November 2007.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Critical Pathways. Gastrectomy. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Chemotherapy, Adjuvant. Drug Combinations. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18701849.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


6. Rohatgi PR, Mansfield PF, Crane CH, Wu TT, Sunder PK, Ross WA, Morris JS, Pisters PW, Feig BW, Gunderson LL, Ajani JA: Surgical pathology stage by American Joint Commission on Cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma. Cancer; 2006 Oct 1;107(7):1475-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical pathology stage by American Joint Commission on Cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma.
  • BACKGROUND: Preoperative chemoradiation for localized gastric cancer can modify baseline stage, as determined by surgical pathology stage.
  • Therefore, the authors hypothesized that surgical pathology stage would be a better prognosticator of overall survival (OS) than baseline stage.
  • METHODS: Patient populations were combined from 2 prospectively conducted, preoperative chemoradiation trials that used the same therapeutic strategy.
  • Patients must have had localized gastric adenocarcinoma and were staged extensively, including endoscopic ultrasonography and laparoscopy.
  • Patients had to be fit for surgery medically with a technically resectable cancer.
  • Patients first received induction chemotherapy for up to 2 months followed by chemoradiation (45 grays) and an attempted surgery.
  • OS was correlated with pretreatment and posttreatment parameters, including surgical pathology stage according to American Joint Commission on Cancer criteria.
  • None of the pretreatment parameters correlated with OS; however, longer OS correlated with lower pathologic stage (P < .0001), R0 resection (P < .001), clinical response noted prior to surgery (P = .002), pathCR (P = .004), lower pathologic lymph node classification (P = .006), and lower pathologic tumor classification (P = .03).
  • Pathologic stage and R0 resection were independent prognostic factors for OS (multivariate Cox model; both P = .05).
  • CONCLUSIONS: When preoperative chemoradiation strategy was employed for gastric cancer, the surgical pathology stage, a reflection of cancer's biologic heterogeneity, was a better prognosticator of OS than the baseline clinical stage.
  • Surgical pathology stage, in this setting, may serve as an intermediate endpoint for Phase II/III trials.
  • [MeSH-major] Carcinoma / mortality. Carcinoma / pathology. Stomach Neoplasms / mortality. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 16944539.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


7. Koo DH, Lee JL, Kim TW, Chang HM, Ryu MH, Yook JH, Oh ST, Kim BS, Lee JS, Kang YK: Adjuvant chemotherapy with 5-fluorouracil, doxorubicin and mitomycin-C (FAM) for 6 months after curative resection of gastric carcinoma. Eur J Surg Oncol; 2007 Sep;33(7):843-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy with 5-fluorouracil, doxorubicin and mitomycin-C (FAM) for 6 months after curative resection of gastric carcinoma.
  • AIM: This study aimed to evaluate the efficacy and safety of 5-fluorouracil (5-FU), doxorubicin and mitomycin-C (FAM) adjuvant chemotherapy in patients who had undergone curative resection of gastric carcinoma.
  • METHODS: From Nov 1999 to Jan 2002, 291 consecutive patients with stage IB-IIIB gastric adenocarcinoma were given FAM adjuvant chemotherapy.
  • Chemotherapy comprised intravenous 5-FU 600 mg/m(2) (days 1, 8, 29 and 36), doxorubicin 30 mg/m(2) (days 1 and 29) and mitomycin-C 10 mg/m(2) (day 1), every 8 weeks for 6 months.
  • RESULTS: The median follow-up time was 60.6 months, 92 patients died, and 93 patients had recurrent disease.
  • The 5-year overall survival (OS) rates were 85.9% for stage IB, 72.1% for stage II, 58.0% for stage IIIA, and 48.2% for stage IIIB (p=0.002).
  • The 5-year relapse-free survival (RFS) rates were 85.2% for stage IB, 71.2% for stage II, 53.3% for stage IIIA, and 39.2% for stage IIIB (p<0.001).
  • A total of 769 cycles of chemotherapy were delivered, and 15 patients experienced grade 3 or higher leukopenia.
  • CONCLUSIONS: Adjuvant chemotherapy with FAM for 6 months for gastric carcinoma indicated comparable RFS and OS with an acceptable toxicity profile.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrectomy / methods. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Female. Fluorouracil / administration & dosage. Fluorouracil / therapeutic use. Follow-Up Studies. Humans. Incidence. Korea / epidemiology. Male. Middle Aged. Mitomycin / administration & dosage. Mitomycin / therapeutic use. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Retrospective Studies. Survival Rate / trends. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17207959.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; U3P01618RT / Fluorouracil; FAM protocol
  •  go-up   go-down


8. Lin WL, Li DG, Chen Q, Lu HM: Clinical and experimental study of oxaliplatin in treating human gastric carcinoma. World J Gastroenterol; 2004 Oct 1;10(19):2911-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and experimental study of oxaliplatin in treating human gastric carcinoma.
  • AIM: To evaluate the therapeutic effectiveness of oxaliplatin on human gastric carcinoma and to explore its mechanisms.
  • METHODS: Twenty-two cases of stage IV gastric carcinoma received 4-6 (mean 4.6) cycles of first line combined chemotherapy with oxaliplatin (oxaliplatin 85 mg/m(2), iv, gtt, 1 h, d 1; leukovorin 200 mg/m(2), iv, gtt, 1 h, d 1 and d 2; 5-FU 300 mg/m(2),iv, d 1 and d 2, 5-FU, continuous iv, gtt, 48 h; 1 cycle/2 wk).
  • Response rate, progression-free survival (PFS), total survival time, toxic side effects were evaluated.
  • The inhibitory effect of oxaliplatin on human gastric cell line SGC-7901 was detected and IC(50) was calculated by MTT.
  • Transmission electron microscopy, flow cytometry and TUNEL were performed to evaluate the apoptosis of cell line induced by the drug.
  • Mean PFS was 4.2 mo and mean total survival time was 7.2 mo.
  • Cumulative neurotoxicity (all grade I-II), vomiting and diarrhea, myelosuppression appeared in 93.5%, 20%, 32.9% patients, respectively.
  • However it could be detected at a much higher degree both by flowcytometry and by TUNEL with a statistical significance (68.47+/-7.92% and 8.23+/-2.67%, respectively, P<0.05) after incubated with 1 mmol/L oxaliplatin for 2 d.
  • CONCLUSION: Oxaliplatin is effective and well-tolerated in patients with advanced gastric carcinoma.
  • Oxaliplatin could significantly inhibit the growth of human gastric cell line SGC-7901.
  • The induction of Caspase-3 m-RNA expression, activation of Caspase-3 and promotion of apoptosis may be some of the therapeutic mechanisms of oxaliplatin on gastric carcinoma.
  • Annexin-V-fluorescein labeling flow cytometry is much more sensitive than TUNEL in detecting early stage apoptosis.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Organoplatinum Compounds / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Apoptosis / drug effects. Cell Line, Tumor. Cysteine Proteinase Inhibitors / pharmacology. Female. Humans. Male. Middle Aged. Neoplasm Staging. Oligopeptides / pharmacology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15334700.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cysteine Proteinase Inhibitors; 0 / Oligopeptides; 0 / Organoplatinum Compounds; 0 / acetyl-aspartyl-glutamyl-valyl-aspartal; 04ZR38536J / oxaliplatin
  • [Other-IDs] NLM/ PMC4572132
  •  go-up   go-down


9. Albregts M, Hulshof MC, Zum Vörde Sive Vörding PJ, van Lanschot JJ, Richel DJ, Crezee H, Fockens P, van Dijk JD, González González D: A feasibility study in oesophageal carcinoma using deep loco-regional hyperthermia combined with concurrent chemotherapy followed by surgery. Int J Hyperthermia; 2004 Sep;20(6):647-59
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A feasibility study in oesophageal carcinoma using deep loco-regional hyperthermia combined with concurrent chemotherapy followed by surgery.
  • This phase I-II study investigated the feasibility of external deep loco-regional hyperthermia in localized primarily operable carcinoma of the thoracic oesophagus and gastro-oesophageal junction.
  • Toxicity when combining neo-adjuvant hyperthermia with concurrent chemotherapy (CDDP and etoposide) was evaluated.
  • The combined treatment courses were repeated every 3 weeks for a maximum of four courses.
  • Pre-treatment tumour stage mainly consisted of T3N1 (stage III) tumours, with a mean length of 6 cm.
  • Combined hyperthermia and chemotherapy was given 55 times in 26 patients.
  • Twenty-two patients underwent oesophageal-cardia resection with gastric tube reconstruction.
  • There was no report of complications in the post-operative phase, which could be contributed to either the prior chemotherapy or the hyperthermia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophageal Neoplasms / therapy. Hyperthermia, Induced / methods
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Adenocarcinoma / therapy. Adult. Aged. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / surgery. Carcinoma, Squamous Cell / therapy. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Etoposide / administration & dosage. Etoposide / adverse effects. Feasibility Studies. Female. Humans. Male. Middle Aged. Neoplasm Staging. Patient Selection. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15370820.001).
  • [ISSN] 0265-6736
  • [Journal-full-title] International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  • [ISO-abbreviation] Int J Hyperthermia
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Kodera Y, Ishiyama A, Yoshikawa T, Kinoshita T, Ito S, Yokoyama H, Mochizuki Y, Ito H, Tsuburaya A, Sakamoto J, Nakao A, Chubu Clinical Cancer Group: A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for gastric carcinoma (CCOG0703). Gastric Cancer; 2010 Aug;13(3):197-203
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for gastric carcinoma (CCOG0703).
  • BACKGROUND: The outcome of stage III gastric cancer patients treated by D2 dissection followed by adjuvant chemotherapy with S-1 remains unsatisfactory.
  • Moreover, some patients with a preoperative diagnosis of stage II/III turn out to be stage IV after surgical exploration, and a standard postoperative treatment for this population has not been established.
  • METHODS: A feasibility study of postoperative S-1/cisplatin (CDDP) was performed with patients who underwent gastrectomy for what turned out to be a stage IV gastric cancer.
  • The primary endpoint of the trial was the relative dose intensity during five courses of S-1/CDDP.
  • The median relative dose intensities of S-1 and CDDP were 37% and 40%, respectively.
  • Causes of treatment failure were failure to fulfill criteria for starting a new course within 5 weeks of the last administration of S-1 in 7, patient refusal in 6, disease recurrence/progression in 4, need to reduce dose by two levels in 4, and two successive skips of CDDP in 3 patients.
  • The median progression-free survival time of all patients was 363 days.
  • CONCLUSIONS: Although promising in the neoadjuvant and advanced/metastatic setting, S-1/CDDP is too toxic as a postgastrectomy treatment for Japanese patients.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Oxonic Acid / therapeutic use. Postoperative Care. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease Progression. Dose-Response Relationship, Drug. Drug Combinations. Feasibility Studies. Female. Gastrectomy. Humans. Japan. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Survival Analysis. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2010 May;21(5):1001-5 [19875759.001]
  • [Cites] N Engl J Med. 2008 Jan 3;358(1):36-46 [18172173.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):25-30 [11957041.001]
  • [Cites] Gastric Cancer. 2006;9(2):129-35 [16767369.001]
  • [Cites] Lancet Oncol. 2008 Mar;9(3):215-21 [18282805.001]
  • [Cites] Gastric Cancer. 2004;7(2):104-9 [15224197.001]
  • [Cites] Gastric Cancer. 2008;11(4):192-3 [19132479.001]
  • [Cites] Gastric Cancer. 2006;9(2):51-66 [16767357.001]
  • [Cites] Am J Surg. 2004 Mar;187(3):440-5 [15006580.001]
  • [Cites] Gastric Cancer. 2007;10(2):129-34 [17577624.001]
  • [Cites] Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3402-7 [16740764.001]
  • [Cites] Oncology. 2007;73(1-2):65-71 [18334851.001]
  • [Cites] Gastric Cancer. 2007;10(1):29-34 [17334715.001]
  • [Cites] Oncology. 2000 Apr;58(3):191-7 [10765119.001]
  • [Cites] N Engl J Med. 2007 Nov 1;357(18):1810-20 [17978289.001]
  • [Cites] Eur J Cancer. 1998 Oct;34(11):1715-20 [9893658.001]
  • [Cites] Int J Cancer. 1999 Sep 24;83(1):18-29 [10449602.001]
  • [Cites] Br J Cancer. 2003 Dec 15;89(12):2207-12 [14676796.001]
  • [Cites] Jpn J Clin Oncol. 2008 Jul;38(7):504-6 [18617536.001]
  • [Cites] Oncology. 2008;74(1-2):37-41 [18544958.001]
  • [Cites] Eur J Surg Oncol. 2009 Nov;35(11):1158-63 [19328643.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] Ann Oncol. 2005 Sep;16(9):1488-97 [15939717.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Dec;132(12):781-5 [16804723.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • (PMID = 20820990.001).
  • [ISSN] 1436-3305
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Sakurai Y, Kamoshida S, Furuta S, Sunagawa R, Inaba K, Isogaki J, Komori Y, Uyama I, Tsutsumi Y: [Predictive value of orotate phosphoribosyltransferase in chemoresistant patients with gastric carcinoma who underwent S-1-based neoadjuvant/adjuvant chemotherapy]. Gan To Kagaku Ryoho; 2008 Jul;35(7):1147-55
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Predictive value of orotate phosphoribosyltransferase in chemoresistant patients with gastric carcinoma who underwent S-1-based neoadjuvant/adjuvant chemotherapy].
  • S-1, a most effective DPD-inhibitory fluoropyrimidine, used as neoadjuvant/adjuvant chemotherapy has recently been shown to improve clinical outcome in patients with stage II and III advanced stage gastric carcinoma.
  • Orotate phosphoribosyltransferase(OPRTEC 2.4.2.10)is a primary enzyme involved in the first-step phosphorylation process of 5-fluorouracil and is an important enzyme that possibly enables to predict sensitivity to S-1 irrespective of tissue DPD levels.
  • To test the hypothesis that a low OPRT level in gastric carcinoma tissue is an indicator of chemoresistance to S-1-based chemotherapy, the predictive value of OPRT levels in chemoresistance was evaluated in patients with gastric carcinoma undergoing S-1-based-neoadjuvant/adjuvant chemotherapy using survival analyses.
  • A total of 67 patients with advanced-stage gastric carcinoma who underwent S-1-based neoadjuvant/adjuvant chemotherapy were subjected to the study.
  • The OPRT level was determined by an enzyme-linked immunosorbent assay(ELISA)that has recently been developed.
  • The patients who underwent S-1-based adjuvant/neoadjuvant chemotherapy(n=67)were divided into 2 groups using various cut-off values to determine the prognostic significance of the OPRT level.
  • In particular, there was a significant difference in the survival rates between Group L and Group H in stage III patients(p<0.05 by logrank test).
  • The multivariate analysis using Cox' proportional hazard model indicated that venous invasion of carcinoma(>v2), lymph node metastasis(>5), and low OPRT level (OPRT<2.0 ng/mg protein) were significant prognostic factors in patients who were underwent S-1-based neoadjuvant/adjuvant chemotherapy.
  • These results suggest that patients with a low OPRT level(OPRT<2.0 ng/mg protein)are non-responders to S-1- based adjuvant/neoadjuvant chemotherapy.
  • The determination of OPRT levels in gastric carcinoma tissue enables to predict the response to S-1-based neoadjuvant/adjuvant chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Neoplasm / drug effects. Orotate Phosphoribosyltransferase / metabolism. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / enzymology. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Drug Combinations. Female. Humans. Male. Neoadjuvant Therapy. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633253.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; EC 2.4.2.10 / Orotate Phosphoribosyltransferase
  •  go-up   go-down


12. Topuz E, Basaran M, Saip P, Aydiner A, Argon A, Sakar B, Tas F, Uygun K, Bugra D, Aykan NF: Adjuvant intraperitoneal chemotherapy with cisplatinum, mitoxantrone, 5-fluorouracil, and calcium folinate in patients with gastric cancer: a phase II study. Am J Clin Oncol; 2002 Dec;25(6):619-24
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant intraperitoneal chemotherapy with cisplatinum, mitoxantrone, 5-fluorouracil, and calcium folinate in patients with gastric cancer: a phase II study.
  • Gastric carcinoma remains one of the leading causes of cancer-related death in the world.
  • Clinical studies have revealed that approximately two thirds of the patients seek treatment for early recurrence within the abdominal cavity.
  • The aim of this phase II study was to evaluate the toxicity, feasibility, and efficacy of adjuvant intraperitoneal chemotherapy (IPCT) with cisplatin, mitoxantrone, 5-fluorouracil (5-FU), and folinic acid in patients with stage II-III gastric cancer.
  • Patients with stage II and III gastric cancer aged between 15 and 70 years, after curative resection, with adequate liver, renal, and cardiac function were included in the study.
  • The chemotherapy regimen consisted of cisplatin 60 mg/m2, mitoxantrone 12 mg/m2, 5-FU 600 mg/m2, and folinic acid 60 mg/m2, delivered intraperitoneally, diluted in 2 l normal saline.
  • However, adjuvant IPCT has similar survival rates in comparison to no adjuvant treatment; thus, it cannot be currently recommended outside the context of a clinical trial.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Infusions, Parenteral. Leucovorin / administration & dosage. Male. Middle Aged. Mitoxantrone / administration & dosage. Survival Analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12478012.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BZ114NVM5P / Mitoxantrone; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


13. Konings IR, van der Gaast A, van der Wijk LJ, de Jongh FE, Eskens FA, Sleijfer S: The addition of pravastatin to chemotherapy in advanced gastric carcinoma: a randomised phase II trial. Eur J Cancer; 2010 Dec;46(18):3200-4
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The addition of pravastatin to chemotherapy in advanced gastric carcinoma: a randomised phase II trial.
  • PURPOSE: Statins have for long been considered to play a potential role in anticancer treatment based upon their ability to inhibit the mevalonate synthesis pathway.
  • This randomised phase II trial compared the efficacy and safety of pravastatin added to epirubicin, cisplatin and capecitabine (ECC versus ECC+P) in patients with advanced gastric carcinoma.
  • For early termination in case of futility, a two-stage design was applied (P(0) = 50%; P(1) = 70%; α = 0.05; β = 0.10).
  • PFR(6 months) was 6/14 patients (42.8%) in the ECC+P arm, and 7/15 patients (46.7%) in the control arm, and therefore the study was terminated after the first stage.
  • CONCLUSION: In this randomised phase II trial the addition of pravastatin to ECC did not improve outcome in patients with advanced gastric cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20727735.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 3Z8479ZZ5X / Epirubicin; 6804DJ8Z9U / Capecitabine; KXO2KT9N0G / Pravastatin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


14. Zhan YQ, Sun XW, Li W, Chen YB, Xu L, Guan YX, Li YF, Xu DZ: [Multivariate prognostic analysis in gastric carcinoma patients after radical operation]. Ai Zheng; 2005 May;24(5):596-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multivariate prognostic analysis in gastric carcinoma patients after radical operation].
  • BACKGROUND & OBJECTIVE: Whether received radical operation is an important prognostic factor of gastric carcinoma.
  • This study was to investigate prognostic factors of gastric carcinoma.
  • METHODS: Clinical data of 405 patients with gastric carcinoma, received radical operation from Jan.
  • 1985 to Dec. 1995 in Cancer Center of Sun Yat-sen University, were analyzed retrospectively.
  • The 5-year survival rates of patients in pathologic TNM (pTNM) stage I, II, III, and IV were 75.6%, 58.7%, 28.0%, and 18.4%, respectively (P < 0.01).
  • In addition, the 5-year survival rate was higher in patients with perioperative chemotherapy than in patients without perioperative chemotherapy (47.2% vs. 37.8%, P < 0.05).
  • Univariate analysis showed that perioperative chemotherapy, Borrmann type, tumor size, pathologic type, and pTNM stage were prognostic factors of gastric carcinoma.
  • Multivariate analysis showed that pTNM stage, tumor size, and perioperative chemotherapy were independent prognostic factors of gastric carcinoma.
  • CONCLUSIONS: pTNM stage, tumor size, and perioperative chemotherapy are the most significant factors influencing prognosis of gastric carcinoma patients after radical operation.
  • Perioperative chemotherapy contributes to enhance survival rate of gastric carcinoma patients.
  • [MeSH-major] Adenocarcinoma / surgery. Gastrectomy. Stomach Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Signet Ring Cell / drug therapy. Carcinoma, Signet Ring Cell / pathology. Carcinoma, Signet Ring Cell / surgery. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Life Tables. Male. Middle Aged. Neoplasm Staging. Perioperative Care. Prognosis. Proportional Hazards Models. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15890105.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


15. Itoh H, Bando E, Kawamura T, Ii T, Takegawa S, Kiriyama M, Dohba S, Kojima Y, Watanabe K: [A case of stage IV gastric carcinoma with lymph nodes metastases of the paraaorta responding markedly to TS-1]. Gan To Kagaku Ryoho; 2002 Dec;29(13):2549-53
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of stage IV gastric carcinoma with lymph nodes metastases of the paraaorta responding markedly to TS-1].
  • A 64-year-old man had undergone subtotal gastrectomy with a D2 lymphadenectomy for advanced carcinoma of the stomach with paraaortic lymph nodes metastases 12 months earlier.
  • The histopathological findings revealed a well differentiated adenocarcinoma [type 2 macroscopic findings, SE, INF beta, ly2, v1, N2, M1 (LYM)].
  • An abdominal ultrasonography and a computed tomography (CT) revealed lymph node swelling of the paraaorta.
  • After non-curative operation, he has received adjuvant chemotherapy with TS-1 plus CDDP.
  • At first, 100 mg/day of TS-1 was orally administered for three weeks followed by two drug-free weeks, with CDDP (60 mg/m2/day) infused on day 8.
  • Next, the treatment course consisted of four-week consecutive administration of TS-1 (80 mg/day) followed by two drug-free weeks, with biweekly infusion of CDDP at a dose of 15 mg/m2.
  • The patient is now in a good health and continues to undergo low dose TS-1 plus CDDP chemotherapy as an outpatient.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymph Nodes / pathology. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aorta. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Drug Administration Schedule. Drug Combinations. Gastrectomy. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Remission Induction. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12506481.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


16. Park SR, Lee JS, Kim YW, Choi IJ, Ryu KW, Lee JH, Lee JY, Park YL, Park SY, Park YI, Kim NK: Prognostic value of response assessed by RECIST and WHO criteria to neoadjuvant chemotherapy in locally advanced gastric cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):e15647

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of response assessed by RECIST and WHO criteria to neoadjuvant chemotherapy in locally advanced gastric cancer patients.
  • : e15647 Background: In metastatic gastric cancer, the response to chemotherapy is assessed by RECIST or WHO criteria according to the change of tumor size.
  • There are no data, however, on the usefulness of those criteria in evaluating tumor response in the setting of neoadjuvant chemotherapy.
  • The aim of this study was to evaluate the relationship between tumor response to neoadjuvant chemotherapy-as assessed by RECIST and WHO criteria-and clinical outcome in locally advanced gastric cancer (LAGC) patients.
  • METHODS: This study recruited LAGC patients who, from January 2003 through November 2005, entered the neoadjuvant arm of prospective randomized phase II trials comparing neoadjuvant chemotherapy to adjuvant chemotherapy.
  • LAGC was defined as stage III or IV (M0) disease based on computed tomography (CT) according to the Japanese Classification of Gastric Carcinoma.
  • Patients with measurable lesions received 3 cycles of neoadjuvant chemotherapy consisting of docetaxel (36 mg/m<sup>2</sup>) and cisplatin (40 mg/m<sup>2</sup>) on days 1 and 8 every 3 weeks, followed by surgery.
  • RESULTS: After chemotherapy, 40 (95%) patients underwent surgery and the remaining 2 patients showed new distant metastasis on CT scan.
  • Twenty-eight (67%) patients had a clinical response to neoadjuvant chemotherapy according to RECIST/WHO criteria.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962733.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Wu S, Deng X, Zhang P, Xie C, Zhang X, Jin Z: Phase II study of postoperative chemoradiotherapy for esophageal carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15606

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of postoperative chemoradiotherapy for esophageal carcinoma.
  • : e15606 Background: Esophageal squamous cell carcinoma is still a virulent disease diagnosed at late stage and remains a major cause of carcinoma mortality in China.
  • The preoperative chemoradiotherapy had been applied to patients with esophageal carcinoma in an effort to reduce the relapse and improve survival.
  • Intergroup study 0116 demonstrated that postoperative chemoradiotherapy significantly improved overall survival in gastric carcinoma patients.
  • The question remains whether postoperative chemoradiotherapy can improve overall survival in patients with esophageal carcinoma.
  • Our planning study was to investigate the role of postoperative chemoradiotherapy in the multimodality treatment for locally advanced esophageal carcinoma.
  • METHODS: From October 2000 to October 2007, Fifty-two patients who underwent esophagectomy with stage II-III esophageal carcinoma were enrolled.
  • Two cycles of chemotherapy (Paclitaxel 135mg/m<sup>2</sup> d1,cisplatin 20mg/m<sup>2</sup>d1-3) were administered concurrently on days 1-3 and days 29-31 of radiotherapy.
  • RESULTS: Of the total 52 patients, 28 (54%) developed grade 3 or 4 toxicity.At the time of analysis, 23 patients died.
  • The median survival time was 37.2 months.
  • The 2-year local-regional control survival, distant metastasis-free survival and relapse-free survival were 60.01%, 71.38% and 42.01%, respectively.
  • CONCLUSIONS: This novel postoperative chemoradiation regimen for treatment of patients with stage II-III esophageal cancer has a tolerable toxicity and promising 3-year overall survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962684.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Escudero MP, Alonso V, Valencia J, Lastra R, Grandez R, Polo S, Ruiz de Lobera A, Polo E, Anton A, Tres A: Adjuvant postoperative chemoradiotherapy in gastric carcinoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):4168

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant postoperative chemoradiotherapy in gastric carcinoma.
  • : 4168 Background: To evaluate the impact of postoperative external radiation therapy combined with 5-Fluorouracil (5FU)-based chemotherapy on the disease-free and overall survival of patients with resected gastric adenocarcinoma.
  • METHODS: Patients with pathological T3/T4 or N+ gastric adenocarcinoma were treated with postgastrectomy chemoradiotherapy.
  • External radiotherapy was administered to the tumor bed and regional nodes, and 2 cm beyond the proximal and distal margins of resection (45 Gy/25 fractions).
  • Chemotherapy: Group A: 5-FU 425 mg/m<sup>2</sup>/d + LV 20 mg/m<sup>2</sup> on days 1-5 every four weeks for two cycles before and after radiation therapy.
  • During radiation therapy with 5-FU protracted continuous infusion (225 mg/m<sup>2</sup>/d) was administered.
  • Group B: Mitomicin C 20 mg/m<sup>2</sup> on day 1 (single dose) followed by Tegafur 500 mg/m<sup>2</sup>/d for six months, even during radiation therapy Results: 40 patients have been included (20 group A, 20 group B).
  • Pathologic stage: II 12p, IIIA 14p, IIIB 7p, IV-M0 7p.
  • The locoregional relapse rate was low probably due to the radiation therapy addition.
  • However the distant metastases rate and the median overall survival seem to be hardly modified by the treatment.
  • We need to find a better scheme of chemotherapy for further studies in order to improve these results.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013766.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Altinbas M, Kaplan B, Ucar K, Ozkan M, Karahacioglu E, Er O, Kucuk C, Soyuer I: 5-FU plus leucovorin (Mayo Regimen) for concurrent chemoradiotherapy after surgery in patients with resectable locally advanced gastric carcinoma: Preliminary results of a phase II study. J Clin Oncol; 2004 Jul 15;22(14_suppl):4196

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 5-FU plus leucovorin (Mayo Regimen) for concurrent chemoradiotherapy after surgery in patients with resectable locally advanced gastric carcinoma: Preliminary results of a phase II study.
  • : 4196 Background: Patients with locoregionally advanced carcinoma of the stomach have a grim outcome due to frequent local and systemic recurrences after surgery.
  • To potentially increase the local control or survival rate and decrease relapses, we investigated a strategy of concurrent chemoradiotherapy and followed by consolidation chemotherapy after surgery.
  • METHODS: Operable 71 patients (Stage IB-IV, M0) underwent total or subtotal gastrectomy.
  • Adjuvant chemotherapy (250 mg/m2 5-FU) was administered concurrently on the first day of every radiotherapy weeks [which was totally standart field radiotherapy (RT), or total abdominal field RT up to 20 Gy first, then returned to standart field RT], .
  • After chemoradiotherapy regimen, consolidation chemotherapy consisted of 450 mg/mg 5-FU plus 20 mg/m2 Leucovorin was applied up to four cycles, q28 d.
  • Six patients in both arms did not get consolidation chemotherapy.
  • There were no deaths related to chemotherapy, chemoradiotherapy, or surgery.
  • CONCLUSIONS: Preliminary results suggest the feasibility of postoperative adjuvant chemoradiotherapy with 5-FU followed by consolidation chomotherapy with MAYO regimen in gastric cancer with acceptable toxicities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013890.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Jouhadi H, Sahraoui S, Acharki A, Benider A: Adjuvant chemotherapy for gastric carcinomas with positive lymph nodes: Experience with a weekly schedule of irinotecan + 5 FU + folinic acid. J Clin Oncol; 2004 Jul 15;22(14_suppl):4258

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy for gastric carcinomas with positive lymph nodes: Experience with a weekly schedule of irinotecan + 5 FU + folinic acid.
  • : 4258 Background: Locally advanced gastric carcinoma is very frequent in Morocco.
  • In spite of a surgery often satisfactory and an adjuvant chemotherapy based on 5 FU+ Cisplatine, the 2 years survival remains low hardly passing the 50% .
  • METHODS: It is a prospective study led between September 2000 and September 2001 that included 34 patient with gastric carcinoma.
  • On the histological plan, 28 patients had a well differentiated adenocarcinoma and 6 patients an undifferentiated carcinoma.
  • The TNM stage was like follows: T3 in 29 cases and T4 in 5 cases; N1 in 19 cases, N2 in 10 cases and N3 in 5 cases.
  • The protocol of chemotherapy consisted in 8 weekly successive injections of: irinotecan 80 mg/m2 + 5 Fluorouracile: 750 mg/m2 + folinic acidic 20 mg/m2.
  • RESULTS: As regards to tolerance, a grade III neutropenia has been observed in 3 cases and a grade II diarrhea observed among 7 patients. at 2 years The disease free survival was 61%.
  • The 2 years DFS is increased with this protocol to 61%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014061.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Jeung HC, Rha SY, Noh SH, Min JS, Kim BS, Chung HC: Adjuvant 5-fluorouracil plus doxorubicin in D2-3 resected gastric carcinoma: 15-year experience at a single institute. Cancer; 2001 Jun 1;91(11):2016-25
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant 5-fluorouracil plus doxorubicin in D2-3 resected gastric carcinoma: 15-year experience at a single institute.
  • BACKGROUND: The authors evaluated the efficacy of adjuvant chemotherapy with 5-fluorouracil (5-FU) plus doxorubicin in gastric carcinoma after D2-3 curative resection.
  • METHODS: A total of 301 patients with Stage II to IV (en bloc resected T4b; 1984 American Joint Committee on Cancer staging) were accrued between 1984 and 1996.
  • Chemotherapy was started within 4 weeks of surgery according to the following schedule: intravenous bolus injection of doxorubicin 40 mg/m2 every 3 weeks for 12 cycles and 5-FU 400 mg/m2 weekly for 60 weeks.
  • Sixty-four percent of the total patients and 71.7% of the patients who did not experience recurrence during the chemotherapy finished the protocol completely with acceptable toxicities.
  • Treatment completion group showed survival benefit over the early termination group in 5-year survival (75.2% vs. 52.9%; P = 0.0005).
  • Multivariate analysis demonstrated that completion of chemotherapy is an independent prognostic factor of both disease free and overall survival.
  • CONCLUSIONS: Adjuvant chemotherapy with 5-FU plus doxorubicin for 60 weeks after D2-3 dissection induced promising survival duration with acceptable toxicities.
  • Full administration of the planned dosage of the combined drugs is recommendable as opposed to early termination of the chemotherapy in gastric carcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Doxorubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Infusions, Intravenous. Injections, Intravenous. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11391580.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; U3P01618RT / Fluorouracil
  •  go-up   go-down


22. Kim R, Yoshida K, Toge T: Current status and future perspectives of post-operative adjuvant therapy for gastric carcinoma. Anticancer Res; 2002 Jan-Feb;22(1A):283-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current status and future perspectives of post-operative adjuvant therapy for gastric carcinoma.
  • The clinical benefit of post-operative adjuvant immunochemotherapy for survival of patients with gastric carcinoma is unclear, although a number of prospective randomized controlled studies have been conducted.
  • The current status and future perspectives of post-operative adjuvant chemotherapy in gastric carcinoma have been evaluated in terms of survival benefit.
  • A meta-analysis, however, indicated a survival benefit in patients treated with post-operative adjuvant chemotherapy including mitomycin, anthracyclines, cyclophosphamide, alkylating agents and 5-fluorouracil (odds ratio: 0.8 to approximately 0.82, 95% CI<1.0).
  • The survival benefit was observed in patients with stage II and stage III gastric carcinoma, but not those with stage I.
  • Although combination therapy with mitomycin, 5-fluorouracil and non-specific immunomodulators, such as PSK and OK-432, appeared to improve overall survival without immunomodulators, the survival effect of immunomodulators is still not clear.
  • There are several possible reasons why the survival benefit of adjuvant chemotherapy or immunochemotherapy is small and marginal compared to surgery alone: (i) low efficacy of the chemotherapy regimen;.
  • (ii) small sample size; and (iii) differences in chemosensitivity of treated patients based on genetic background.
  • The determination of subgroups responsive to chemotherapy and the development of a rationale-based and molecular-targeted chemotherapy are required to clearly demonstrate whether there is a survival benefit of post-operative adjuvant chemotherapy in gastric carcinoma.
  • [MeSH-major] Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. Forecasting. Humans. Immunotherapy. Randomized Controlled Trials as Topic. Survival Analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12017304.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Number-of-references] 57
  •  go-up   go-down


23. Chen JS, Chao Y, Bang YJ, Roca E, Chung HC, Palazzo F, Kim YH, Myrand SP, Mullaney BP, Shen LJ, Linn C: A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma. Anticancer Drugs; 2010 Sep;21(8):777-84
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma.
  • This phase I/II study was conducted to determine the maximum recommended dose of pemetrexed when given in combination with a fixed dose of cisplatin, and the efficacy, toxicity and association of 5,10-methylenetetrahydrofolate reductase (MTHFR) variants with this pemetrexed--cisplatin combination, in patients with unresectable, advanced gastric carcinoma.
  • Patients 18-70 years of age, with stage IV disease or post-surgery recurrence, no earlier palliative chemotherapy, 0 or 1 Eastern Cooperative Oncology Group performance status, were included.
  • In phase II, efficacy, including overall response rate, overall survival, as well as toxicity and MTHFR pharmacogenetics were investigated.
  • Phase II enrolled 73 patients, 69 qualified for safety and 68 for efficacy analysis; 65 for pharmacogenomic analysis.
  • Patients with MTHFR A1298C variants had median overall survival of 6.6 months, significantly shorter than patients with the wild type (median 18.5 months, P=0.001).
  • The pemetrexed--cisplatin combination in patients with advanced gastric cancer generates modest efficacy and a manageable toxicity profile.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Glutamates / therapeutic use. Guanine / analogs & derivatives. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Folic Acid Antagonists / administration & dosage. Folic Acid Antagonists / adverse effects. Folic Acid Antagonists / pharmacology. Humans. Male. Membrane Transport Proteins / genetics. Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Middle Aged. Pemetrexed. Pharmacogenetics. Survival Analysis. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827860047 for PMID:20634689 [PharmGKB] .
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20634689.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Folic Acid Antagonists; 0 / Glutamates; 0 / Membrane Transport Proteins; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); Q20Q21Q62J / Cisplatin
  •  go-up   go-down


24. Kodera Y, Ito S, Fujiwara M, Mochizuki Y, Ohashi N, Ito Y, Nakayama G, Koike M, Yamamura Y, Nakao A: In vitro chemosensitivity test to predict chemosensitivity for paclitaxel, using human gastric carcinoma tissues. Int J Clin Oncol; 2006 Dec;11(6):449-53
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro chemosensitivity test to predict chemosensitivity for paclitaxel, using human gastric carcinoma tissues.
  • BACKGROUND: Therapy guided by chemotherapy sensitivity and resistance assays may lead to rational treatment decisions.
  • Paclitaxel, one of several new drugs for gastric carcinoma, has not been extensively evaluated by in vitro chemosensitivity tests.
  • METHODS: Chemosensitivity testing by histoculture drug response assay (HDRA) was performed with fresh specimens of primary tumor from 113 patients with gastric carcinoma.
  • HDRA was successfully performed for 100 of 113 samples and chemosensitivity, calculated as the percentage of optical density of a tumor treated with anticancer drugs in relation to the optical density of the tumor cultured in the medium only, was distributed widely at this concentration.
  • No significant correlation was observed between chemosensitivity and age, sex, clinical stage, histopathologic type, and outcome of patients with gastric carcinoma.
  • CONCLUSION: A histoculture drug response assay can now be performed to predict the chemosensitivity of paclitaxel at the concentration found in the current study.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Drug Resistance, Neoplasm. Paclitaxel / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Culture Techniques. Drug Screening Assays, Antitumor. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Sensitivity and Specificity. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):259-67 [16344314.001]
  • [Cites] Surg Today. 2002;32(6):477-81 [12107769.001]
  • [Cites] Anticancer Res. 1999 Sep-Oct;19(5C):4581-6 [10650814.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2282-7 [12805327.001]
  • [Cites] Gastric Cancer. 2002;5(2):90-5 [12111584.001]
  • [Cites] Int J Oncol. 2005 Sep;27(3):637-44 [16077911.001]
  • [Cites] Jpn J Clin Oncol. 2005 Nov;35(11):672-5 [16275676.001]
  • [Cites] Methods Mol Med. 2005;110:59-67 [15901927.001]
  • [Cites] Cancer Sci. 2003 Jan;94(1):112-8 [12708484.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):10-24 [11957040.001]
  • [Cites] Br J Cancer. 2001 Apr 6;84(7):878-80 [11286464.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):422-31 [15659489.001]
  • [Cites] Eur J Cancer. 1998 Oct;34(11):1715-20 [9893658.001]
  • [Cites] Anticancer Res. 2003 Jul-Aug;23 (4):3147-50 [12926047.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3618-30 [15289487.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] Lancet. 1999 Jul 24;354(9175):273-7 [10440302.001]
  • [Cites] Cancer Res. 1988 Jul 15;48(14):4093-100 [2898289.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3810-5 [10577853.001]
  • (PMID = 17180513.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


25. Kostić Z, Cuk V, Bokun R, Ignjatović D, Usaj-Knezević S, Ignjatović M: [Detection of free cancer cells in peritoneal cavity in patients surgically treated for gastric adenocarcinoma]. Vojnosanit Pregl; 2006 Apr;63(4):349-56
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of free cancer cells in peritoneal cavity in patients surgically treated for gastric adenocarcinoma].
  • BACKGROUND/AIM: Peritoneal metastasis is a leading cause of therapeutic failure after an operative treatment of patients with gastric adenocarcinoma.
  • Free cancer cells might induce or indicate an early peritoneal seeding with a subsequent peritoneal metastasis.
  • The aim of this study was to determine the frequency of the presence of free cancer cells in the peritoneal cavity in the patients surgically treated for gastric adenocarcinoma, and its relation to certain clinical, operative and pathohistological paramethers.
  • Immediately after the laparotomy, 200 ml physiologic saline, heated to 37 degrees C, was introduced into the abdominal cavity, mannualy dispersed and collected from the region around the gastric tumor and the pouch of Douglas.
  • The cytological findings were defined as positive or negative according to the presence of cancer cells.
  • The frequency of positive cytological findings was compared to the location and the diameter of the cancer, pathohistological type of carcinoma, pathohistological stage of the disease, lymph node and the liver and/or peritoneal metastases and the type of surgical procedure.
  • RESULTS: Free cancer cells were found in 24 (24%) of the patients, while in 76 (76%) of them cytological findings were negative.
  • A statistically highly significant difference (p < or = 0.001) in the frequency of positive cytological finding was found between the groups of patients with and without cancer invasion of serosa, with cancer diameters > 5 cm and < or = 5 cm, in the stage of disease I, II and III, IV, with macroscopically present and without metastases, with re section and D2 lymphadenectomy and palliative procedure.
  • Free cancer cells were statistically more frequently (p < or = 0.05) detected in the patients with lymph nodes metastases comparing to the patients with out lymph nodes involvement.
  • The results of the univariate analysis showed that the cancer diameter > 5 cm, tumor invasion of serosa, pathohistological stage of the disease III and IV and macroscopically visible metastases were the most important risk factors for the free cancer cells detection.
  • CONCLUSION: Peritoneal lavage cytology was shown to be a useful tool for the detection of the group of patients with greatest risk of peritoneal dissemination.
  • The frequency of positive cytological findings was highly associated with the diameter of the tumor and the cancer invasion of serosa.
  • Cytological examination of peritoneal lavage fluid improved the accuracy of staging and selection of patients who might have benefit from neoadjuvant chemotherapy.
  • [MeSH-major] Adenocarcinoma / surgery. Neoplasm Seeding. Neoplastic Cells, Circulating. Peritoneal Cavity / cytology. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Vojnosanit Pregl. 2006 Apr;63(4):347-8 [16683400.001]
  • (PMID = 16683401.001).
  • [ISSN] 0042-8450
  • [Journal-full-title] Vojnosanitetski pregled
  • [ISO-abbreviation] Vojnosanit Pregl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


26. Ito S, Kodera Y, Mochizuki Y, Kojima T, Nakanishi H, Yamamura Y: Phase II clinical trial of postoperative S-1 monotherapy for gastric cancer patients with free intraperitoneal cancer cells detected by real-time RT-PCR. World J Surg; 2010 Sep;34(9):2083-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II clinical trial of postoperative S-1 monotherapy for gastric cancer patients with free intraperitoneal cancer cells detected by real-time RT-PCR.
  • BACKGROUND: We have previously reported the molecular detection of peritoneal micrometastases in patients with gastric cancer by quantifying carcinoembryonic antigen (CEA) mRNA in the peritoneal washes.
  • Patients with CEA mRNA exceeding a cutoff value have a significant risk for developing peritoneal carcinomatosis, but optimal treatment for this population remains unknown.
  • METHODS: CEA mRNA (+) patients with gastric cancer were treated postoperatively with S-1 monotherapy.
  • Overall survival, the primary endpoint of this phase II trial, was compared with the historical control, which is comprised of CEA mRNA (+) patients who were not given postoperative chemotherapy.
  • RESULTS: A total of 32 patients with CEA mRNA (+) gastric cancer were enrolled.
  • CONCLUSIONS: S-1 monotherapy, which significantly reduced risk for recurrence in stage II/III gastric carcinoma in another phase III trial, seems not to be as effective in eradicating free cancer cells in the abdominal cavity.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Oxonic Acid / administration & dosage. Peritoneal Neoplasms / secondary. Stomach Neoplasms / drug therapy. Stomach Neoplasms / mortality. Tegafur / administration & dosage
  • [MeSH-minor] Carcinoembryonic Antigen / analysis. Chemotherapy, Adjuvant. Disease-Free Survival. Drug Combinations. Female. Humans. Kaplan-Meier Estimate. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Peritoneal Lavage. Reverse Transcriptase Polymerase Chain Reaction. Risk Assessment

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] World J Surg. 2011 Feb;35(2):468-9; author reply 470-1 [20857104.001]
  • [Cites] J Am Coll Surg. 2006 Feb;202(2):231-6 [16427547.001]
  • [Cites] Hepatogastroenterology. 2007 Apr-May;54(75):960-3 [17591103.001]
  • [Cites] Gastric Cancer. 2008;11(4):206-13 [19132482.001]
  • [Cites] Gastric Cancer. 2006;9(4):308-14 [17235634.001]
  • [Cites] Ann Surg Oncol. 2007 May;14 (5):1694-702 [17294072.001]
  • [Cites] Jpn J Cancer Res. 1997 Jul;88(7):687-92 [9310142.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Int J Cancer. 2000 Sep 20;89(5):411-7 [11008202.001]
  • [Cites] Clin Cancer Res. 1997 May;3(5):653-9 [9815733.001]
  • [Cites] Langenbecks Arch Surg. 2005 Sep;390(5):430-41 [15991048.001]
  • [Cites] Gastric Cancer. 2004;7(2):104-9 [15224197.001]
  • [Cites] Int J Oncol. 2005 Sep;27(3):637-44 [16077911.001]
  • [Cites] Jpn J Clin Oncol. 2005 Nov;35(11):672-5 [16275676.001]
  • [Cites] Br J Surg. 1990 Apr;77(4):436-9 [2340396.001]
  • [Cites] Anticancer Drugs. 1996 Jul;7(5):548-57 [8862723.001]
  • [Cites] Lancet Oncol. 2003 May;4(5):277-83 [12732164.001]
  • [Cites] Br J Cancer. 2005 Oct 31;93(9):986-92 [16205696.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;43 Suppl:S32-6 [10357556.001]
  • [Cites] Gynecol Oncol. 2001 Sep;82(3):581-9 [11520161.001]
  • [Cites] Oncology. 2000 Apr;58(3):191-7 [10765119.001]
  • [Cites] N Engl J Med. 2007 Nov 1;357(18):1810-20 [17978289.001]
  • [Cites] Eur J Cancer. 1998 Oct;34(11):1715-20 [9893658.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1441-7 [8336183.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):361-8 [16428473.001]
  • [Cites] Eur J Surg Oncol. 2009 Nov;35(11):1158-63 [19328643.001]
  • [Cites] Int J Cancer. 1998 Aug 21;79(4):429-33 [9699538.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2609-16 [18451223.001]
  • [Cites] Ann Surg. 2002 Apr;235(4):499-506 [11923605.001]
  • (PMID = 20379713.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Carcinoembryonic Antigen; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


27. Ohi S, Takahashi N, Ninomiya K, Nakajima M, Hashimoto H, Tachibana T, Yanaga K, Ishikawa H: Establishment and characterization of a cisplatin-resistant cell line (IGSK-1) from a poorly differentiated gastric adenocarcinoma. Hum Cell; 2007 Feb;20(1):15-22
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment and characterization of a cisplatin-resistant cell line (IGSK-1) from a poorly differentiated gastric adenocarcinoma.
  • We successfully established a spontaneously cisplatin-resistant tumor cell line (designated as IGSK-1) derived from original gastric carcinoma.
  • The histopathological diagnosis was gastric poorly differentiated adenocarcinoma accompanied with metastatic foci in lymph nodes, pT3, N2 M0, stage IIIB.
  • The susceptibility of the IGSK-1 cells to anti-cancer drugs was examined using oxygen electrode apparatus (Daikin, Tsukuba, JPN), and the results suggested TXL was effective, and CDDP, CPT-11 and 5-FU were not effective.
  • Spontaneously cisplatin-resistant gastric carcinoma cell line secreted gastrin and somatostatin is very important material for chemotherapy.
  • [MeSH-major] Adenocarcinoma / pathology. Antineoplastic Agents / pharmacology. Cell Line, Tumor. Cisplatin / pharmacology. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Drug Screening Assays, Antitumor. Female. Gastrins / metabolism. Humans. Somatostatin / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1989 Dec 15;44(6):1100-3 [2606577.001]
  • [Cites] Cancer Res. 1975 Aug;35(8):2025-32 [1170940.001]
  • [Cites] Hum Cell. 1991 Mar;4(1):67-70 [1888706.001]
  • [Cites] Jpn J Exp Med. 1978 Feb;48(1):61-8 [209229.001]
  • [Cites] Cancer Res. 1990 May 1;50(9):2773-80 [2158397.001]
  • [Cites] Pathol Int. 2000 Oct;50(10):767-77 [11107048.001]
  • [Cites] Cancer Sci. 2004 Jul;95(7):575-82 [15245593.001]
  • [Cites] Hum Cell. 1989 Sep;2(3):307-9 [2562403.001]
  • [Cites] Int J Cell Cloning. 1987 Jul;5(4):322-34 [3497992.001]
  • [Cites] Hum Cell. 2005 Mar;18(1):35-44 [16130898.001]
  • [Cites] Acta Med Okayama. 1976 Jun;30(3):215-9 [136873.001]
  • [Cites] Jpn J Surg. 1988 Jul;18(4):438-46 [3172586.001]
  • [Cites] Gastroenterol Jpn. 1989 Apr;24(2):219 [2744340.001]
  • (PMID = 17506773.001).
  • [ISSN] 0914-7470
  • [Journal-full-title] Human cell
  • [ISO-abbreviation] Hum. Cell
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Gastrins; 51110-01-1 / Somatostatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


28. Sato H, Hori K, Sugiyama K, Tanda S, Sato Y: [Tumor microcirculation and selective enhancement of drug delivery--clinical applications based on pathophysiological experiments]. Gan To Kagaku Ryoho; 2000 Jul;27(8):1191-200
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tumor microcirculation and selective enhancement of drug delivery--clinical applications based on pathophysiological experiments].
  • Tumor tissue is composed of cancer cells (parenchyma) and tumor vessels (interstitium).
  • This would be a certain cause of insufficient drug delivery to tumor tissues.
  • Among the experimental evidence using Yoshida Sarcoma and Ascites Hepatomas, functional differences in microcirculation between tumor and normal tissues were found by Suzuki et al. (1977).
  • Under hypertensive state induced by the continuous infusion of angiotensin II, tumor blood flow increased remarkably, while there was no change or decrease in blood flow in normal tissues such as the brain, bone marrow, liver and kidney.
  • Augmentation of the anti-tumor effects of angiotensin II-induced hypertension chemotherapy (IHC) for advanced gastric carcinoma was revealed in two randomized controlled trials (RCT-1 & 2) of collaborative study groups in Japan.
  • In the results of phase II studies from 1978 to 1994 (OPN-1) and 1995 to 1999 (OPN-2) for advanced gastric carcinoma (GC), the response rates were 37.9% and 35.7%.
  • Down staging in which the conclusive stage score was lower than the score of the clinical stage, was observed in 8 out of 94 cases (19%) with primary lesions in total and in 30 patients (63%) receiving reduction surgery after IHC, since 1978.
  • It is very important for exact evaluation after chemotherapy to understand or estimate the pathohistological changes in the tumor and its degenerated or repaired tissues, which present various clinical images.
  • IHC with smaller DI could lead to a reduction in the accumulation of toxicities of anti-cancer drugs in the host.
  • In conclusion, IHC might be applied to all kinds of tumors to enhance the chemotherapeutic effects through selective increase of drug delivery to tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Delivery Systems / methods. Sarcoma, Yoshida / blood supply. Sarcoma, Yoshida / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Animals. Blood Pressure / drug effects. Doxorubicin / administration & dosage. Drug Administration Schedule. Fluorouracil / administration & dosage. Humans. Microcirculation. Mitomycin / administration & dosage. Rats

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10945016.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; U3P01618RT / Fluorouracil; FAM protocol
  • [Number-of-references] 77
  •  go-up   go-down


29. Zhao X, Huang K, Zhu Z, Chen S, Hu R: Correlation between expression of leptin and clinicopathological features and prognosis in patients with gastric cancer. J Gastroenterol Hepatol; 2007 Aug;22(8):1317-21
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between expression of leptin and clinicopathological features and prognosis in patients with gastric cancer.
  • BACKGROUND: The relationship between the expression of leptin in the tissue of gastric cancer and the clinicopathological features as well as patients' outcome were investigated.
  • METHODS: Sixty-one gastric cancer specimens were investigated by immunohistochemical studies with anti-leptin and anti-vascular endothelial growth factor (VEGF) antibodies and by monitoring patients for at least 3 years after surgery.
  • RESULTS: A positive rate of leptin expression was significantly associated with Borrmann classification (Borrmann type 1 and type 2 68.2% vs Borrmann type 3 and type 4 or unclassified 35.3%), tumor histology (well differentiated tumors 87.5% vs poorly differentiated tumors 48.9%), lymph node metastasis (with 69.0% vs without 36.8%) and stage (stage III + IV 69.0% vs stage I + II 36.8%).
  • The Cox proportional hazards model identified serosal involvement, tumor size, metastasis, tumor histology, leptin expression, lymph node metastasis, age and postoperative chemotherapy as significant prognostic factors.
  • CONCLUSIONS: The expression of leptin in the tissue of gastric cancer was significantly associated with tumor histology, Borrmann classification, lymph node metastasis and stage of gastric cancer.
  • In patients with poorly differentiated gastric cancer, a poor prognosis was found in those with a strong expression of leptin.
  • [MeSH-major] Carcinoma / metabolism. Leptin / metabolism. Stomach Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17559372.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Leptin; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


30. Moehler M, Schimanski CC, Gockel I, Junginger T, Galle PR: (Neo)adjuvant strategies of advanced gastric carcinoma: time for a change? Dig Dis; 2004;22(4):345-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] (Neo)adjuvant strategies of advanced gastric carcinoma: time for a change?
  • Despite surgical R0 resections, patients with gastric cancer stage UICC II-III have a high risk of recurrence and metachronic metastases.
  • Preliminary evidence exists that adjuvant chemotherapy or neoadjuvant chemo(radio)therapy protocols may improve the prognosis of these patients undergoing surgery of gastric cancer with curative intention.
  • Upcoming cytostatic agents, i.e. irinotecan, docetaxel, oxaliplatin, and oral fluoropyridines are currently under investigation in new multimodality treatment regimens and may further increase R0 resection rates and may prolong disease-free and overall survival in the treatment of advanced localized gastric cancer.
  • [MeSH-major] Carcinoma / pathology. Carcinoma / therapy. Neoadjuvant Therapy / standards. Stomach Neoplasms / pathology. Stomach Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2004 S. Karger AG, Basel.
  • (PMID = 15812158.001).
  • [ISSN] 0257-2753
  • [Journal-full-title] Digestive diseases (Basel, Switzerland)
  • [ISO-abbreviation] Dig Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 52
  •  go-up   go-down


31. Stein HJ, Feith M, Siewert JR: Cancer of the esophagogastric junction. Surg Oncol; 2000 Jul;9(1):35-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer of the esophagogastric junction.
  • Epidemiological, clinical and pathological data support a sub-classification of adenocarcinomas arising in the vicinity of the esophagogastric junction (AEG) into adenocarcinoma of the distal esophagus (Type I), true carcinoma of the cardia (Type II) and subcardial carcinoma (Type III).
  • While most, if not all, adenocarcinomas of the distal esophagus arise from areas with specialized intestinal metaplasia, which develop as a consequence of chronic gastroesophageal reflux, the etiology and pathogenesis of true carcinoma of the gastric cardia and subcardial gastric cancer is not clear at present.
  • Although a subgroup of true carcinomas of the gastric cardia may also develop within short segments of intestinal metaplasia at the esophagogastric junction, a causal relation between these tumors and gastroesophageal reflux has been difficult to establish.
  • Our experience in the management of more than 1000 such patients during the past 18 years suggests that an individualized therapeutic strategy oriented by tumor type and stage results in survival rates superior to those reported with a more indiscriminate approach.
  • This individualized strategy prescribes a transmediastinal esophagectomy with lymphadenectomy in the lower posterior mediastinum and along the celiac axis for Type I tumors, extended total gastrectomy with transhiatal resection of the distal esophagus and D2 lymphadenectomy for Type II and Type III tumors, a limited resection of the esophagogastric junction and distal esophagus with interposition of a pedicled jejunal segment for uT1N0 tumors, and neoadjuvant chemotherapy followed by resection for uT3/T4 tumors.
  • Extensive preoperative staging is essential to allow correct selection of the appropriate therapeutic strategy using this tailored approach.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / therapy. Esophageal Neoplasms / diagnosis. Esophageal Neoplasms / therapy. Esophagogastric Junction. Stomach Neoplasms / diagnosis. Stomach Neoplasms / therapy
  • [MeSH-minor] Algorithms. Combined Modality Therapy. Decision Trees. Esophagectomy. Gastrectomy. Gastroesophageal Reflux / complications. Humans. Incidence. Lymph Node Excision. Neoplasm Staging. Preoperative Care. Prevalence. Splenectomy. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11525305.001).
  • [ISSN] 0960-7404
  • [Journal-full-title] Surgical oncology
  • [ISO-abbreviation] Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 36
  •  go-up   go-down


32. Kato K, Koide A, Oobu M, Hasegawa K, Maruyama S, Takashima I, Nagahama T, Maruyama M, Ebuchi M: [A case of gastric cancer with peritoneal dissemination which shows a remarkable efficacy by a weekly administration of paclitaxel intraperitoneally]. Gan To Kagaku Ryoho; 2004 Oct;31(11):1852-4
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of gastric cancer with peritoneal dissemination which shows a remarkable efficacy by a weekly administration of paclitaxel intraperitoneally].
  • We treated a 65-year-old female with gastric cancer who underwent peritoneal dissemination after 6 successive weeks of paclitaxel intraperitoneal therapy (90 mg/body), and obtained a disappearance of ascites and a reduction of the primary carcinoma.
  • Operative findings: U ant, type 5, 26x20 mm, por, T2, n1(+), H0, P0, CY0, M0, stage II, and grade 2.
  • A weekly paclitaxel intraperitoneal therapy could be a useful for both peritoneal dissemination and the primary carcinoma of advanced gastric carcinoma.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Neoplasm Seeding. Paclitaxel / administration & dosage. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Drug Administration Schedule. Female. Humans. Injections, Intraperitoneal. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15553737.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Biomarkers, Tumor; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


33. Kim JP, Yu HJ, Lee JH: Results of immunochemo-surgery for gastric carcinoma. Hepatogastroenterology; 2001 Sep-Oct;48(41):1227-30
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of immunochemo-surgery for gastric carcinoma.
  • BACKGROUND/AIMS: Although the therapeutic results of gastric cancer have markedly improved, it still remains the most common cancer death in Korea.
  • METHODOLOGY: The clinicopathologic characteristics were analyzed for 11,491 consecutive patients who underwent operation for gastric cancer at the Department of Surgery, Seoul National University Hospital from 1971 to 1997.
  • The prognostic significance of treatment modality [surgery alone, surgery + chemotherapy, surgery + immunotherapy + chemotherapy (immunochemo-surgery)] were evaluated in stage III gastric cancer.
  • The 5-year survival rates according to TNM stage were 92.9% for Ia, 84.2% for Ib, 69.3% for II, 45.8% for IIIa, 29.6% for IIIb and 9.2% for IV.
  • Regarding adjuvant treatment modality, significant survival difference was observed in stage III patients.
  • The 5-year survival rates were 44.8% for the immunochemo-surgery group, 36.8% for the surgery + chemotherapy group and 27.2% for the surgery alone group.
  • CONCLUSIONS: Curative resection, depth of invasion and lymph node metastasis were the most significant prognostic factors in gastric cancer.
  • Consequently, early detection and curative resection with radical lymph node dissection, followed by immunochemotherapy especially in patients with stage III gastric cancer should be recommended as a standard treatment principle for patients with gastric cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Picibanil / therapeutic use. Stomach Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Randomized Controlled Trials as Topic. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11677936.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 39325-01-4 / Picibanil
  •  go-up   go-down


34. Takemura M, Osugi H, Lee S, Taguchi S, Kaneko M, Tanaka Y, Fukuhara K, Fujiwara Y, Nishizawa S, Kinoshita H, Harada S: [A case of synchronous esophageal and gastric cancer successfully treated by combination TS-1/CDDP therapy with irradiation]. Gan To Kagaku Ryoho; 2004 Feb;31(2):251-4
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of synchronous esophageal and gastric cancer successfully treated by combination TS-1/CDDP therapy with irradiation].
  • We report a case of synchronous esophageal and gastric cancer in a patient with severe liver dysfunction who was treated successfully using TS-1/CDDP therapy combined with irradiation therapy.
  • A 56-year-old man with a chief complaint of dysphagia was diagnosed with thoracic esophageal cancer by endoscopy, and was referred to our hospital.
  • Synchronous esophageal and gastric cancer were diagnosed by endoscopy and barium swallow.
  • The preoperative diagnosis was T3N0M0, Stage II esophageal cancer and T1N0M0, Stage I A gastric cancer, both of which were diagnosed to be resectable.
  • TS-1 (80 mg/day) and CDDP (3 mg/day) therapy was combined with irradiation, 60 Gy given in a T-pattern to the mediastinum.
  • The patient did not suffer any side-effects, and endoscopy performed 44 days after the start of treatment showed that the esophageal lesion was now only a scar.
  • Only a slight elevation of the esophagus was seen by endoscopy 219 days after the start of the therapy.
  • The patient is currently undergoing only TS-1 treatment as an outpatient and is under observation.
  • TS-1 and CDDP therapy combined with radiotherapy appears to be effective in treating thoracic esophageal cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy. Neoplasms, Multiple Primary. Stomach Neoplasms / drug therapy. Stomach Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Administration, Oral. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Drug Combinations. Humans. Male. Middle Aged. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Radiotherapy Dosage. Tegafur / administration & dosage

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14997762.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


35. Liang QL, Pan DC, Yin ZM, Liu GX, Yang Q, Xie JR, Cai LZ, Fu YW: [Clinical value of serum soluble Apo-1/Fas for predicting biological behaviors and prognosis of gastric carcinoma]. Ai Zheng; 2002 Feb;21(2):174-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical value of serum soluble Apo-1/Fas for predicting biological behaviors and prognosis of gastric carcinoma].
  • BACKGROUND & OBJECTIVE: Literatures reported that the soluble Apo-1/Fas(sApo-1/Fas) levels in serum of patients with malignant carcinoma were higher than that in normal control subject, but there were fewer studies was seldom to detect the level of sApo-1/Fas in patients with malignancy carcinoma and effect of chemotherapy; the subject is to detect the level of sApo-1/Fas in patients with gastric carcinoma and effect of chemotherapy on it, and to investigate its clinical value.
  • METHODS: Enzyme linked immunosorbent assays(ELISA) was available to detect the level of sApo-1/Fas in 42 case of patients with gastric carcinoma before and after chemotherapy, as compared with 30 case of normal control subject.
  • RESULTS: Levels of sApo-1/Fas were elevated in all subgroups of patients with gastric carcinoma as compared to the controls (P < 0.01), sApo-1/Fas was correlated with clinical stage and histological grade, and not with sex, age; the sApo-1/Fas level in stage IV was higher in comparison with stage III and II (P < 0.05-0.01), and in stage III it was higher than in stage II (P < 0.05); being lower in the well differentiated and moderately differentiated than the poorly differentiated(P < 0.05-0.01), that the sApo-1/Fas levels were remarkably reduced in complete remission or partial remission patients(P < 0.01) after chemotherapy.
  • CONCLUSION: sApo-1/Fas may play closely reflect growth and regulation in gastric carcinoma, it may be a predictor for biological behaviors and prognosis of gastric carcinoma; sApo-1/Fas may be a new target in treating gastric carcinoma.
  • [MeSH-major] Antigens, CD95 / blood. Stomach Neoplasms / blood

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12479070.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD95
  •  go-up   go-down


36. Pedersen MØ, Larsen A, Stoltenberg M, Penkowa M: The role of metallothionein in oncogenesis and cancer prognosis. Prog Histochem Cytochem; 2009;44(1):29-64
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of metallothionein in oncogenesis and cancer prognosis.
  • The antiapoptotic, antioxidant, proliferative, and angiogenic effects of metallothionein (MT)-I+II has resulted in increased focus on their role in oncogenesis, tumor progression, therapy response, and patient prognosis.
  • Studies have reported increased expression of MT-I+II mRNA and protein in various human cancers; such as breast, kidney, lung, nasopharynx, ovary, prostate, salivary gland, testes, urinary bladder, cervical, endometrial, skin carcinoma, melanoma, acute lymphoblastic leukemia (ALL), and pancreatic cancers, where MT-I+II expression is sometimes correlated to higher tumor grade/stage, chemotherapy/radiation resistance, and poor prognosis.
  • However, MT-I+II are downregulated in other types of tumors (e.g. hepatocellular, gastric, colorectal, central nervous system (CNS), and thyroid cancers) where MT-I+II is either inversely correlated or unrelated to mortality.
  • Large discrepancies exist between different tumor types, and no distinct and reliable association exists between MT-I+II expression in tumor tissues and prognosis and therapy resistance.
  • Furthermore, a parallel has been drawn between MT-I+II expression as a potential marker for prognosis, and MT-I+II's role as oncogenic factors, without any direct evidence supporting such a parallel.
  • This review aims at discussing the role of MT-I+II both as a prognostic marker for survival and therapy response, as well as for the hypothesized role of MT-I+II as causal oncogenes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19348910.001).
  • [ISSN] 0079-6336
  • [Journal-full-title] Progress in histochemistry and cytochemistry
  • [ISO-abbreviation] Prog Histochem Cytochem
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 9038-94-2 / Metallothionein
  • [Number-of-references] 203
  •  go-up   go-down


37. Wang W, Li YF, Sun XW, Chen YB, Li W, Xu DZ, Guan XX, Huang CY, Zhan YQ, Zhou ZW: Prognosis of 980 patients with gastric cancer after surgical resection. Chin J Cancer; 2010 Nov;29(11):923-30
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of 980 patients with gastric cancer after surgical resection.
  • BACKGROUND AND OBJECTIVE: Although surgery is the only possible means to cure gastric cancer, the prognosis is often discrepant.
  • The American Joint Committee on Cancer / International Union against Cancer (AJCC/UICC) published the TNM classification of Malignant Tumors (seventh edition) for gastric cancer recently.
  • This study aimed to use this new edition staging system to investigate the prognostic factors for gastric cancer.
  • METHODS: The clinicopathologic data of 980 patients with gastric cancer treated by surgical resection in our hospital between January 2000 and December 2006 were analyzed retrospectively.
  • The 6th and 7th edition AJCC/UICC TNM staging systems were used to compare the survival outcomes for the cohort of patients.
  • The 5-year survival rates for patients with pTNM stage I, II, III, and IV disease classified by the 7th edition staging system were 93.2%, 72.4%, 39.1%, and 5.2%, respectively.
  • In both univariate analysis and Cox multivariate analysis, age, tumor site, tumor size, histological type, resection type, radical resection, lymphatic/venous invasion, depth of invasion, nodal status, metastasis, retrieved lymph nodes, metastatic lymph node ratio, and adjuvant chemotherapy were prognostic factors with these patients.
  • CONCLUSION: Compared with the 6th edition system, the new edition of TNM staging system for gastric cancer can accurately predict the survival after operation.
  • [MeSH-major] Adenocarcinoma. Gastrectomy. Neoplasm Staging / standards. Stomach Neoplasms
  • [MeSH-minor] Adenocarcinoma, Mucinous / classification. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Signet Ring Cell / classification. Carcinoma, Signet Ring Cell / pathology. Carcinoma, Signet Ring Cell / surgery. Cohort Studies. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Proportional Hazards Models. Retrospective Studies. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20979691.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] China
  •  go-up   go-down


38. Gilliam AD, Watson SA, Henwood M, McKenzie AJ, Humphreys JE, Elder J, Iftikhar SY, Welch N, Fielding J, Broome P, Michaeli D: A phase II study of G17DT in gastric carcinoma. Eur J Surg Oncol; 2004 Jun;30(5):536-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of G17DT in gastric carcinoma.
  • The aim of the study was to characterise antibody response and assess safety and tolerability of G17DT given to patients with gastric cancer.
  • EXPERIMENTAL DESIGN: G17DT was administered to 52 patients with gastric adenocarcinoma at weeks 0, 2 and 6 by intramuscular injection at doses of 10, 100 and 250 microg.
  • RESULTS: By week 12 of the study, 6/12 evaluable stage I-III patients achieved an antibody response in the 10 microg group, 7/11 in the 100 microg group, and 11/12 in the 250 microg group.
  • Stage IV patients dosed at 250 microg achieved a similar response rate to stage I-III patients dosed at 10 or 100 microg.
  • CONCLUSIONS: G17DT immunisation is a well-tolerated method of raising functional antibodies to 17 amino acid gastrin forms in patients with gastric carcinomas.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / immunology. Antibody Formation / drug effects. Cancer Vaccines / administration & dosage. Gastrins. Stomach Neoplasms / drug therapy. Stomach Neoplasms / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Immune Sera / drug effects. Immune Sera / immunology. Immunization, Secondary. Injections, Intramuscular. Male. Middle Aged. Neoplasm Staging. Receptor, Cholecystokinin B / drug effects. Receptor, Cholecystokinin B / immunology. Statistics as Topic. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15135483.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Controlled Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Gastrins; 0 / Immune Sera; 0 / Receptor, Cholecystokinin B; 0 / gastrin immunogen
  •  go-up   go-down


39. Furuse K, Kawahara M, Hasegawa K, Kudoh S, Takada M, Sugiura T, Ichinose Y, Fukuoka M, Ohashi Y, Niitani H, S-1 Cooperative Study Group (Lung Cancer Working Group): Early phase II study of S-1, a new oral fluoropyrimidine, for advanced non-small-cell lung cancer. Int J Clin Oncol; 2001 Oct;6(5):236-41
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early phase II study of S-1, a new oral fluoropyrimidine, for advanced non-small-cell lung cancer.
  • BACKGROUND: The efficacy and safety of S-1, a new oral fluoropyrimidine, were evaluated in patients with non-small-cell lung cancer (NSCLC).
  • The objective of this study was to determine whether the drug should be investigated in a late phase II study.
  • METHODS: Each treatment course consisted of an oral dose of S-1, 50 mg/body or 75 mg/body, twice a day for 28 days followed by a 2-week washout period.
  • These effects disappeared after cessation of the drug or appropriate treatment.
  • CONCLUSION: S-1 showed modest activity with mild toxicity in the treatment of non-small-cell lung cancer.
  • Based on this result, we will progress to the next stage of a late phase II study for advanced NSCLC, and a phase II study of S-1 and cisplatin for advanced gastric cancer.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Pyridines / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Administration, Oral. Adult. Aged. Confidence Intervals. Drug Combinations. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • Genetic Alliance. consumer health - Oral cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11723745.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


40. Ku Y, Iwasaki T, Tominaga M, Fukumoto T, Takahashi T, Kido M, Ogata S, Takahashi M, Kuroda Y, Matsumoto S, Obara H: Reductive surgery plus percutaneous isolated hepatic perfusion for multiple advanced hepatocellular carcinoma. Ann Surg; 2004 Jan;239(1):53-60
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reductive surgery plus percutaneous isolated hepatic perfusion for multiple advanced hepatocellular carcinoma.
  • OBJECTIVE: To evaluate the efficacy of a novel 2-stage treatment with reductive surgery plus percutaneous isolated hepatic perfusion (PIHP) for multiple hepatocellular carcinoma (HCC), which was previously unresectable.
  • SUMMARY BACKGROUND DATA: Surgical resection is the treatment of choice for HCC, but the majority of patients with advanced HCC are not suitable candidates.
  • PIHP is a minimally invasive surgery that allows high-dose regional chemotherapy of the liver, and our phase II studies have shown its profound efficacy for the local control of advanced HCC.
  • In the first stage, all patients underwent reductive hepatectomy: major hepatectomy in 13 patients and segmentectomy or less in 12.
  • Regardless of the type of hepatectomy, all patients routinely underwent cholecystectomy, and ligations of the right gastric artery and arterial collaterals of the remnant liver to increase the safety and efficacy of PIHP.
  • In the second stage, PIHP with doxorubicin 60-120 mg/m2/treatment was planned for a period of 1 to 3 months after surgery.
  • RESULTS: Of 25 enrolled patients, 22 successfully underwent PIHP an average of 1.8 times for the local control of residual liver tumors.
  • In 22 patients with the 2-stage treatment, 19 (86%) had objective local tumor control (10 complete remissions and 9 partial responses with a median response duration of 16 months).
  • CONCLUSIONS: Reductive surgery plus PIHP produced a strong antitumoral effect on multiple advanced HCC, when liver function allows this concentrated treatment approach, and offers long-term survival in a subset of patients who were previously deemed to have unresectable disease.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Chemotherapy, Cancer, Regional Perfusion / methods. Doxorubicin / administration & dosage. Hepatectomy / methods. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Biopsy, Needle. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Probability. Prospective Studies. Risk Assessment. Statistics, Nonparametric. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 1998 Oct 15;129(8):643-53 [9786813.001]
  • [Cites] Surgery. 1992 Sep;112(3):515-21 [1325673.001]
  • [Cites] Ann Surg. 1999 Jul;230(1):1-8 [10400029.001]
  • [Cites] Ann Surg. 2000 Sep;232(3):381-91 [10973388.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Surgery. 1990 Mar;107(3):273-81 [2106730.001]
  • [Cites] Gastroenterology. 1993 Aug;105(2):488-94 [8392955.001]
  • [Cites] Surg Today. 1993;23(8):675-81 [8400670.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2723-36 [7989950.001]
  • [Cites] Cancer. 1995 Feb 1;75(3):794-800 [7530166.001]
  • [Cites] Surgery. 1995 May;117(5):510-9 [7740422.001]
  • [Cites] Radiology. 1995 Oct;197(1):101-8 [7568806.001]
  • [Cites] Surgery. 1996 May;119(5):517-22 [8619206.001]
  • [Cites] Am J Surg. 1997 Feb;173(2):103-9 [9074373.001]
  • [Cites] J Gastroenterol Hepatol. 1997 Oct;12(9-10):S319-28 [9407353.001]
  • [Cites] Ann Surg. 1998 Mar;227(3):433-9 [9527067.001]
  • [Cites] Ann Surg. 1998 Apr;227(4):519-26 [9563540.001]
  • [Cites] Cancer. 1999 Nov 1;86(9):1682-90 [10547540.001]
  • [Cites] World J Surg. 1986 Apr;10(2):311-7 [3010585.001]
  • [Cites] Ann Surg. 1990 Mar;211(3):277-87 [2155591.001]
  • [Cites] Ann Surg. 1991 Aug;214(2):114-7 [1714267.001]
  • [Cites] Cancer. 1992 Feb 15;69(4):925-9 [1310435.001]
  • [Cites] Hepatology. 1992 Aug;16(2):353-7 [1322349.001]
  • [Cites] Am J Surg. 1999 Apr;177(4):303-6 [10326848.001]
  • (PMID = 14685100.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin
  • [Other-IDs] NLM/ PMC1356192
  •  go-up   go-down


41. Stein HJ, Feith M, Siewert JR: Individualized surgical strategies for cancer of the esophagogastric junction. Ann Chir Gynaecol; 2000;89(3):191-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Individualized surgical strategies for cancer of the esophagogastric junction.
  • Due to their borderline location between the stomach and esophagus the optimal surgical strategy for patients with adenocarcinoma of the esophagogastric junction is controversial.
  • Irrespective of the surgical approach a complete removal of the primary tumor and its lymphatic drainage has to be the primary goal of surgical treatment of such tumors.
  • Based on the experience with surgical resection of more than 1000 patients with adenocarcinoma of the esophagogastric junction we recommend an individualized surgical strategy guided by tumor stage and topographic location of the tumor center or tumor mass.
  • This requires detailed preoperative staging and classification of tumors arising in the vicinity of the esophagogastric junction into adenocarcinoma of the distal esophagus (AEG Type I Tumors), true carcinoma of the gastric cardia (AEG Type II Tumors) and subcardial gastric carcinoma infiltrating the esophagogastric junction (AEG Type III Tumors).
  • In patients with Type I Tumors transthoracic esophagectomy offers no survival benefit over radical transmediastinal esophagectomy, but is associated with higher morbidity.
  • In patients with Type II or Type III tumors an extended total gastrectomy results in equal or superior survival and less postoperative mortality than a more extended esophagogastrectomy.
  • In patients with early tumors, staged as uT1 on preoperative endosonography, a limited resection of the proximal stomach, cardia and distal esophagus with interposition of a pedicled isoperistaltic jejunal segment allows a complete tumor removal with adequate lymphadenectomy and offers excellent functional results.
  • Multimodal treatment protocols with neoadjuvant chemotherapy or combined radiochemotherapy followed by surgical resection appear to markedly improve the prognosis in patients with locally advanced tumors who respond to preoperative treatment.
  • With this tailored approach extensive preoperative staging becomes mandatory for an adequate selection of the appropriate therapeutic concept.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma / surgery. Cardia. Esophageal Neoplasms / surgery. Esophagogastric Junction. Stomach Neoplasms / surgery
  • [MeSH-minor] Algorithms. Chemotherapy, Adjuvant. Clinical Trials, Phase III as Topic. Combined Modality Therapy. Endoscopy. Esophagectomy. Esophagus / pathology. Gastrectomy. Gastric Fundus / surgery. Humans. Neoplasm Staging. Palliative Care. Prognosis. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic. Stomach / pathology. Time Factors

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11079787.001).
  • [ISSN] 0355-9521
  • [Journal-full-title] Annales chirurgiae et gynaecologiae
  • [ISO-abbreviation] Ann Chir Gynaecol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] FINLAND
  • [Number-of-references] 26
  •  go-up   go-down


42. Rojo F, Tabernero J, Albanell J, Van Cutsem E, Ohtsu A, Doi T, Koizumi W, Shirao K, Takiuchi H, Ramon y Cajal S, Baselga J: Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J Clin Oncol; 2006 Sep 10;24(26):4309-16
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma.
  • PURPOSE: Epidermal growth factor receptor (EGFR) is highly expressed in some gastric cancers and is implicated in cancer cell growth and proliferation.
  • The objective of this study was to assess the in situ biologic activity of the EGFR tyrosine kinase inhibitor gefitinib in gastric tumor samples in a phase II study.
  • METHODS: Patients with previously treated stage IV adenocarcinoma of the stomach or gastroesophageal junction were randomly assigned to receive gefitinib (250 or 500 mg/d).
  • Tumor biopsies, obtained at screening and on day 28 of treatment, were assessed for biomarker expression using immunohistochemistry and analysis of apoptosis.
  • RESULTS: One hundred sixteen tumor samples from 70 patients were available, 70 were baseline and 46 were on-therapy biopsies.
  • After gefitinib treatment, levels of pEGFR in tumor cells were significantly reduced (P = .001); this was not the case for pMAPK and phosphorylated Akt (pAkt).
  • CONCLUSION: Gefitinib reached the tumors at concentrations sufficient to inhibit EGFR activation in advanced gastric carcinoma patients, although this did not translate into clinical benefit.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / metabolism. Carcinoma / drug therapy. Quinazolines / therapeutic use. Receptor, Epidermal Growth Factor / metabolism. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis / drug effects. Area Under Curve. Female. Humans. Ki-67 Antigen / metabolism. Male. Middle Aged. Mitogen-Activated Protein Kinase Kinases / metabolism. Protein Kinase Inhibitors / therapeutic use. Proto-Oncogene Proteins c-akt / metabolism. Signal Transduction / drug effects

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2006 Dec 10;24(35):5620. Ramon Cajal, S [corrected to Ramon y Cajal, S]
  • (PMID = 16963731.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases; S65743JHBS / gefitinib
  •  go-up   go-down


43. Swisher SG, Pisters PW, Komaki R, Lahoti S, Ajani JA: Gastroesophageal junction adenocarcinoma. Curr Treat Options Oncol; 2000 Dec;1(5):387-98
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence rate of adenocarcinoma of the esophagogastric junction (AEG) is increasing in association with the epidemiologic rise in distal esophageal adenocarcinoma and gastric cardial (AEG type III) tumors.
  • The overall survival rate is poor in most patients with AEG because lymph node or visceral metastases are frequently present at the time patients become symptomatic.
  • Early stage AEG (T1N0 or T2NO, carcinoma in situ, or severe dysplasia ) can in many instances be cured with surgery alone.
  • Ablative treatments for early stage AEG, including endoscopic fulguration by cautery and laser or photodynamic therapy, are investigational at this time.
  • Locoregionally advanced AEG (T3, T4, N1, or M1a ) without distant systemic metastases (M1b) has a poor overall survival rate with surgery alone or definitive chemotherapy and radiation therapy without surgery.
  • Analysis of the use of multimodality treatment strategies for locoregionally advanced AEG types I and II have demonstrated improved survival rates in two small phase III trials with preoperative concurrent chemoradiotherapy followed by surgical resection.
  • In contrast, three small phase III trials with preoperative concurrent or sequential chemoradiotherapy in patients with predominantly squamous cell carcinoma did not demonstrate any clear survival advantage.
  • Additionally, a randomized phase III study evaluating preoperative chemotherapy without radiation therapy in esophageal cancer (predominantly adenocarcinoma) has demonstrated no survival benefit.
  • At the present time, preoperative chemoradiotherapy remains investigational.
  • For locoregionally advanced gastric adenocarcinoma, including AEG type III, postoperative concurrent 5-fluorouracil (5-FU)-based chemoradiotherapy is associated with improved survival as demonstrated in a recently completed random assignment trial (INT 0116).
  • As a result, surgery with postoperative chemoradiotherapy has recently become the standard of care for patients with AJCC stage II and III gastric adenocarcinoma (including patients with AEG type III).
  • Metastatic AEG (M1b) should be treated with palliative chemotherapy (in good performance patients) or supportive care (poor performance) in asymptomatic patients.
  • Radiation therapy and endoscopic stent placement (expandable wire mesh) can be used to palliate dysphagia in patients with M1b disease.
  • [MeSH-major] Adenocarcinoma / therapy. Esophageal Neoplasms / therapy. Esophagogastric Junction / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Esophagectomy. Humans. Neoplasm Staging. Radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Mar 25;340(12):908-14 [10089184.001]
  • [Cites] N Engl J Med. 1996 Aug 15;335(7):462-7 [8672151.001]
  • [Cites] Clin Radiol. 1995 Jan;50(1):11-4 [7530613.001]
  • [Cites] Lancet. 1996 Apr 13;347(9007):995-9 [8606613.001]
  • [Cites] Radiology. 1996 Jun;199(3):648-52 [8637981.001]
  • [Cites] Surgery. 1999 Feb;125(2):142-7 [10026746.001]
  • [Cites] Am J Surg. 1995 Jun;169(6):609-14 [7771626.001]
  • [Cites] J Thorac Cardiovasc Surg. 1993 Nov;106(5):860-6; discussion 866-7 [8231208.001]
  • [Cites] N Engl J Med. 1997 Jul 17;337(3):161-7 [9219702.001]
  • [Cites] J Thorac Cardiovasc Surg. 2000 Jun;119(6):1126-32 [10838528.001]
  • [Cites] World J Surg. 1992 Nov-Dec;16(6):1104-9; discussion 1110 [1455880.001]
  • [Cites] Cancer. 1994 Apr 1;73(7):1779-84 [8137201.001]
  • [Cites] Br J Cancer. 1999 Mar;79(9-10):1522-30 [10188901.001]
  • [Cites] Cancer Res. 1988 Jul 1;48(13):3843-8 [3378219.001]
  • [Cites] Arch Surg. 1996 Aug;131(8):819-24; discussion 824-5 [8712904.001]
  • [Cites] Surgery. 1997 Mar;121(3):278-86 [9092128.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Jul;17(1):49-54 [2745207.001]
  • [Cites] Eur J Cancer Prev. 1992 Apr;1(3):265-9 [1467772.001]
  • [Cites] Lancet. 1995 Mar 25;345(8952):745-8 [7891484.001]
  • [Cites] Gastrointest Endosc. 1995 Dec;42(6):507-12 [8674919.001]
  • [Cites] J Thorac Cardiovasc Surg. 1994 Nov;108(5):813-21; discussion 821-2 [7967662.001]
  • [Cites] J Clin Oncol. 1994 Feb;12(2):417-22 [8113850.001]
  • [Cites] Br J Surg. 1995 Dec;82(12 ):1678-81 [8548240.001]
  • [Cites] Ann Thorac Surg. 1997 Sep;64(3):757-64 [9307470.001]
  • [Cites] N Engl J Med. 1992 Jun 11;326(24):1593-8 [1584260.001]
  • [Cites] Br J Surg. 1988 Aug;75(8):760-3 [3167523.001]
  • [Cites] Ann Thorac Surg. 1997 Sep;64(3):752-6 [9307469.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1441-7 [8336183.001]
  • [Cites] Br J Cancer. 1985 Mar;51(3):399-405 [3970816.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Semin Surg Oncol. 1999 Sep;17 (2):125-31 [10449684.001]
  • [Cites] Cancer. 1961 Mar-Apr;14:389-413 [13786981.001]
  • [Cites] J Natl Cancer Inst. 1981 Aug;67(2):243-51 [6943364.001]
  • [Cites] Gastroenterology. 1993 Feb;104(2):510-3 [8425693.001]
  • [Cites] Cancer Res. 1992 Apr 1;52(7 Suppl):2119s-2123s [1544150.001]
  • [Cites] Gastrointest Endosc. 1998 Aug;48(2):172-9 [9717783.001]
  • [Cites] N Engl J Med. 1998 Dec 31;339(27):1979-84 [9869669.001]
  • [Cites] Gastrointest Endosc. 1996 Mar;43(3):196-203 [8857133.001]
  • [Cites] Int J Cancer. 1985 May 15;35(5):593-7 [3997280.001]
  • [Cites] J Natl Cancer Inst. 1993 Sep 15;85(18):1483-92 [8360931.001]
  • (PMID = 12057146.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 47
  •  go-up   go-down


44. Akaza H, Aiba K, Isonishi S, Ogawa O, Shibuya M, Sone S, Tsuruo T, Noguchi S, Hinotsu S, Kono S, Mikami O, Blackledge G, Vose B, Stribling D: [Development of molecular targeting drugs for the treatment of cancer-therapeutic potential and issues to be addressed in global development]. Gan To Kagaku Ryoho; 2000 Oct;27(11):1681-93
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Development of molecular targeting drugs for the treatment of cancer-therapeutic potential and issues to be addressed in global development].
  • A survey of cancer treatment in a sample of hospitals > 100 beds conducted in 1998 compared with experience in the US showed that good progress has been achieved in Japan in the screening and early treatment of gastric cancer, and that the prognosis for breast cancer is better than in the West.
  • Although in the past, the cytotoxic therapies available to physicians in Japan vs the West have been different, recent acceleration of regulatory review will result in a convergence of treatment paradigms and some improvement in acute response in many tumour types.
  • However, world wide there is a need for new improved therapies in all cancers evaluated.
  • The eventual hope is that cancer can be turned from a lethal disease into a chronic disease where patients maintain a good QOL.
  • Apart from anti hormonal therapies, the usual approach has been to kill the cancerous cells.
  • However, the new approaches to intervening in the growth and migration of cancerous cells or the host tissue response by molecular targeting offer the promise of achieving a step change in therapy.
  • Some compounds will require combination therapy with a conventional cytotoxic or radiotherapy to show their full benefit.
  • However, for the new approaches which will not have such severe dose limiting toxicities, it will be necessary to select a surrogate marker of the intended biological effect to select the optimal biological dose (OBD) and dose regimen in phase I/II studies for further evaluation in phase II or III studies which are designed to show the expected patient benefit.
  • The tumour target, the stage of the disease and the possible need for concomitant therapy will also have to be considered according to the mechanism of action of the product.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Antimetabolites, Antineoplastic / administration & dosage. Apoptosis. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / secondary. Female. Fluorouracil / administration & dosage. Gastrointestinal Neoplasms / drug therapy. Humans. Japan. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Male. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / pathology. United States

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11057319.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down






Advertisement